WO1989002740A1 - 4-aminopyridine derivatives - Google Patents

4-aminopyridine derivatives Download PDF

Info

Publication number
WO1989002740A1
WO1989002740A1 PCT/US1988/001070 US8801070W WO8902740A1 WO 1989002740 A1 WO1989002740 A1 WO 1989002740A1 US 8801070 W US8801070 W US 8801070W WO 8902740 A1 WO8902740 A1 WO 8902740A1
Authority
WO
WIPO (PCT)
Prior art keywords
ppm
formula
group
compound according
amino
Prior art date
Application number
PCT/US1988/001070
Other languages
French (fr)
Inventor
Manoj Chandrasinhji Desai
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to IL87861A priority Critical patent/IL87861A0/en
Priority to ES88309040T priority patent/ES2072263T3/en
Priority to DE3853863T priority patent/DE3853863T2/en
Priority to AT88309040T priority patent/ATE123024T1/en
Priority to EP88309040A priority patent/EP0311303B1/en
Priority to MYPI88001105A priority patent/MY104335A/en
Priority to PL1988275056A priority patent/PL159258B1/en
Priority to PT88656A priority patent/PT88656B/en
Priority to NO884400A priority patent/NO176713C/en
Priority to AU23370/88A priority patent/AU619213B2/en
Priority to NZ226445A priority patent/NZ226445A/en
Priority to IE300388A priority patent/IE60718B1/en
Priority to DK553988A priority patent/DK553988A/en
Priority to CN88109023A priority patent/CN1032440A/en
Priority to KR1019880012933A priority patent/KR900007243B1/en
Priority to FI884553A priority patent/FI93117C/en
Priority to YU184988A priority patent/YU48197B/en
Priority to HU885131A priority patent/HU203082B/en
Priority to JP63251742A priority patent/JPH0692372B2/en
Publication of WO1989002740A1 publication Critical patent/WO1989002740A1/en
Priority to SU925010806A priority patent/RU2039058C1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/61—Carboxylic acid nitriles containing cyano groups and nitrogen atoms being part of imino groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to 4-aminopyridine derivatives.
  • the compounds of the present invention inhibit brain acetylcholinesterase and are useful in the treatment of Alzheimer's disease.
  • Tetrahydroaminoacridine which has anticholinesterase activity, has been reported to produce improved performance in psychological tests in patients afflicted with Alzheimer's disease (W. K. Summers et al., The New England Journal of Medicine, 315, 1241-1245 (1986)).
  • the anticholinesterase physostigmine has also been reportedly used in the experimental treatment of Alzheimer's disease (S. D. Brinkman et al., Neurobiol. Aging, 4, 139-145 (1983)).
  • United States Patent 4,652,567 refers to benzo(C)-1,5-naphthyridines for treating Alzheimer's disease.
  • United States Patent 4,631,286 refers to 9-amino-1,2,3,4-tetrahydroacridine-1-ol and related compounds for treating Alzheimer's disease.
  • United States Patent 4,550,113 refers to 9-amino- 2,3,5,6,7,8-hexahydro-1H-cyclopenta (b) quinoline mono-hydrate hydrochloride for treating neuritis, injuries of the peripheral nervous system, hereditary neuromuscular diseases, and disseminated sclerosis.
  • United States Patent 4,578,394 refers to dihydropyridines for treating Alzheimer's disease.
  • United States Patent 4,540,564 refers to dihydropyridines for delivering drugs to the brain.
  • G. K. Patnaik et al., J. Med. Chem., 9 , 483-488 (1966), refer to 4-substituted 2,3-polymethylenequinolines having analgetic, local anesthetic, analeptic, and respiratory stimulant activities.
  • British Patent Specifications 1,186,061, 1,186,062, and 1,186,063 refer to benzonaphthyridine derivatives.
  • the present invention relates to compounds of the formula
  • A is selected from the group consisting of
  • R 1 is hydrogen or C 1 -C 6 alkyl
  • R 3 is independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkanoyl, di(C 1 -C 6 alkylamino)-C 1 -C 6 alkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, halogen (e.g., fluoro, chloro, bromc or iodo), hydroxy, nitro, phenyl, substituted phenyl, phenyl-C 1 -C 6 alkyl, substituted phenyl-C 1 -C 6 alkyl, diphenyl-C 1 -C 6 alkyl wherein one or both of the phenyl groups may be replaced with a substituted ohenyl group, furyl-C 1 -C 6 alkyl, thienyl-C 1
  • R 4 is independently selected from the possible substituents selected from the group consisting of halogen (e.g., fiuoro, chloro, bromo or iodo), C 1 -C 6 alkyl, trifluoromethyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, hydroxy and nitro, and wherein R 5 , R 6 and R 7 are independently selected from C 1 -C 6 alkyl and C 1 -C 6 alkanoyl; R 2 is independently selected from the group consisting of 1,4-dihydropyridyl-C 1 -C 6 alkanoyl, C 1 -C 6 alkyl-1,4-dihydropyridyl-C 1 -C 6 -alkanoyl, and the possible definitions set forth above for R 3 , except that R 2 cannot be hydroxy, halogen, C 1 -C 6 alkoxy, phenyloxy or substituted phenyloxy; R 4 is independently selected from
  • R 8 is C 1 -C 6 alkyl or C 1 -C 6 alkanoyl
  • Z 1 is O or S
  • Z 5 is
  • Y 3 is
  • Y 2 and Y 3 are CH, with the proviso that when A is a group of the formula 1 wherein R 3 is hydrogen and there is no nitrogen at position a, b, c or d or A is a group of the formula 3 or 4, only one of Y 1 and Y 2 can be
  • the present invention also relates to a pharmaceutical composition for the treatment of Alzheimer's disease comprising a compound of the formula I and to the use of compounds of the formula I in treating Alzheimer's disease.
  • the present invention also relates to methods of preparing compounds of the formula I.
  • One embodiment of the present invention relates to compounds of the formula I wherein R 1 , R 2 , A and B are as defined for formula I, with the proviso that when A is a group of the formula 1 wherein there is no nitrogen at position a, b, c or d or A is a group of the formula 3 or 4, only one of Y 1 and Y 2 can be CH 2 ; and pharmaceutically acceptable salts thereof.
  • One aspect of the foregoing embodiment relates to compounds wherein Y 3 is CH 2 , and at least one of Z 3 and Z 4 is
  • Z 4 can be (CH 2 ) P .
  • a preferred embodiment of the present invention relates to compounds of the formula I wherein A, B, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 and Y 3 are as defined with respect to formula I; R 1 , R 2 and R 4 are hydrogen; and R 3 is hydrogen or halogen; with the proviso that when A is a group of the formula 1 wherein there is no nitrogen at position a,b,c or d, or A is a group of the formula 3 or 4, only one of Y 1 and Y 2 can be CH 2 ; and pharmaceutically acceptable salts thereof.
  • R 3 is halogen
  • the halogen is preferably fluorine.
  • Another preferred embodiment of the present invention relates to compounds of the formula I wherein A is a group of the formula 1, wherein one of the CH moieties at positions a and b of formula 1 may be replaced by a nitrogen atom, cr A is a group of the formula 3;
  • R 1 , R 2 and R 4 are hydrogen and R 3 is hydrogen or halogen.
  • R 3 is halogen, the halogen is preferably fluorine.
  • Another preferred embodiment of the present invention relates to compounds of the formula I, wherein B is a group of the formula 7 or 8 and A, R 1 ,
  • R 2 , R 3 , Z 1 , Z 2 , q, Y 1 , Y 2 and Y 3 are as defined with respect to formula I, with the proviso that when A is a group of the formula 1 wherein there is no nitrogen at position a, b, c, cr d, or A is a group of the formula 3 or 4, only one of Y 1 and Y 2 can be CH 2 ; and pharmaceutically acceptable salts thereof.
  • R 1 and R 2 are hydrogen and R 3 is hydrogen or halogen.
  • R 3 is halogen, the halogen is preferably fluorine.
  • a particularly preferred embodiment of the present invention relates to compounds of the formula Z , wherein A is a group of the formula 1, wherein one of the CH moieties at positions a and b of formula 1 may be replaced by a nitroqen atom, or A is a group of the rormula 3; B is a group of the formula 7 or 8; R 1 , R 2 , R 3 , q, Y 1 , Y 2 and Y 3 are as defined for formula I; and n is 1 or 2; with the proviso that
  • R 1 , R 2 and R 4 are hydrogen and R 3 is hydrogen or halogen.
  • the halogen is preferably fluorine.
  • Another preferred embodiment of the present invention relates to compounds of the formula I, wherein A is a group of the formula 1, wherein R 3 is as defined for formula I, with the proviso that R 3 may only be at position d of formula 1, and R 1 , R 2 and B are as defined for formula I, and the pharmaceutically acceptable salts thereof.
  • R 3 is halogen, more preferably, fluorine.
  • A is a group of the formula 1, wherein R 3 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, hydroxy, nitro, NHCOR 5 ,NR 6 R 7 or trifluoromethyl; B is a group of the formula wherein r is 2,3 or 4; and R 1 ,R 2 ,R 5 ,R 6 and R 7 are as defined for formula I; and the pharmaceutically acceptable salts thereof.
  • R 3 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, hydroxy, nitro, NHCOR 5 ,NR 6 R 7 or trifluoromethyl
  • B is a group of the formula wherein r is 2,3 or 4
  • R 1 ,R 2 ,R 5 ,R 6 and R 7 are as defined for formula I
  • the pharmaceutically acceptable salts thereof are those wherein R 3 is at the d position of formula 1 or wherein R 3 is hal
  • Particularly preferred compounds are those wherein R 3 is halogen at the d position.
  • the halogen is preferably fluorine.
  • Specific preferred compounds of the present invention are the following:
  • compositions of the present invention contain the foregoing preferred compounds. More preferred compositions of the present invention contain the foregoing more preferred compounds and specific preferred compounds.
  • an aminonitrile of the formula II wherein A is as defined above, is reacted with a ketone of the formula III wherein B is as defined above to prepare a ketimine of the formula IV.
  • the reaction is conducted in an inert solvent, preferably an aromatic solvent (e.g., benzene or toluene), in the presence of an acid, preferably a strong acid (e.g. p-toluenesulfonic acid).
  • the temperature should be at least about 100°C, but is otherwise not critical.
  • the reaction is conducted at the reflux temperature of the reaction mixture, e.g., by refluxing the reaction mixture in a Dean Stark apparatus, preferably for about 6 to about 16 hours, and removing the water periodically.
  • the reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere).
  • the crude ketimine IV obtained after the removal of solvent is then reacted with a base (e.g., lithium diisopropylamide) in. an inert solvent, preferably an anhydrous ether (e.g., tetrahydrofuran), at a temperature of about 0°C to about 25°C.
  • a base e.g., lithium diisopropylamide
  • an inert solvent preferably an anhydrous ether (e.g., tetrahydrofuran)
  • the reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere).
  • the first method works especially well when an ail carbon ketone is employed in the reaction.
  • Azeotropic removal 80°C, PTSA, 15 hours) of water from a benzene solution of norcamphor (or an ail carbcr. ketone) and anthranilonitrile afforded the corresponding ketimine which on treatment with lithium diisopropylamide (0°C, 4 hours) in tetrahydrofuran afforded the compound of Example 1 in 25% yield.
  • the use of this procedure is also exemplified by the preparation of the compounds of Examples 2, 3, 4, 30 and 36.
  • the limitation in the general applicability of the first method is the difficulty of formation of ketimines from carbonyl compounds containing a nitrogen or oxygen atom. Titanium (IV) chloride, because of its high affinity for oxygen, has been used in the preparation of ketimines. (See H. Weingarten et al., J. Org. Chem., 32, 3246(1967)). This observation was adapted for the synthesis of 9-amino-1,2,3,4-tetrahydroacridine derivatives in a single step by the condensation of appropriate o-aminonitriles with diverse carbonyl components.
  • a compound of the formula II wherein A is defined as above is reacted with a carbonyl-containing compound of the formula III wherein B is as defined above.
  • the carbonyl-containing compound may be a. ketone, a lactone, or the like.
  • the reaction is conducted in an inert solvent in the presence of a Lewis acid (e.g., titanium (IV) chloride) and, if necessary, in the presence of a base, preferably an amine base (e.g. triethylamine).
  • a Lewis acid e.g., titanium (IV) chloride
  • a base preferably an amine base (e.g. triethylamine).
  • Suitable solvents include aromatic solvents (e.g., benzene cr toluene) and chlorinated solvents (e.g., methylene chloride or 1,2-dichloroethane).
  • aromatic solvents e.g., benzene cr toluene
  • chlorinated solvents e.g., methylene chloride or 1,2-dichloroethane.
  • the reaction temperature should be at least about 0°C and is preferably about 25 to about 120°C.
  • the reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere).
  • Monoalkylation of the amine group in compounds of the present invention may be achieved by heating them with appropriate alkyl halides in the presence of sodium hydride in dimethylformamide. This is exemplified by the synthesis of the compounds of Examples 20-25 and 34.
  • the compounds of Formula I are capable of forming acid addition salts with pharmaceutically acceptable acids.
  • the acid addition salts may be prepared by reacting the base form of the appropriate compound of formula I with one or more equivalents, preferably with an excess, of the appropriate acid in an organic solvent, for example, diethyl ether or an ethanol diethyl ether mixture.
  • Suitable acids to form these salts include the common mineral acids, e.g. hydrohalic, sulfuric or phosphoric acid; the organic acids, e.g. ascorbic, citric, lactic, aspartic or tartaric acid or their aqueous solutions whose pH has been adjusted to 5.5 or less; and acids which are sparingly soluble in body fluids and which impart slow-release properties to their respective salts, e.g. pamoic or tannic acid or carboxymethyl cellulose.
  • the preferred salt is the hydrochloride salt.
  • the compounds of formula I and the pharmaceutically acceptable salts thereof are useful in the treatment of various memory dysfunctions associated with decreased cholinergic function such as Alzheimer's Disease. Additionally, the compounds lead to stimula tion of neuromuscular transmission, enhancement of excitation in excitable tissues (nerve, and smooth and striated muscle) as well as restoration of conductance in nerves, and neuromuscular synapses in the case of injury thereof.
  • the compounds of this invention also exhibit antidepressant activities which is particularly helpful for patients suffering from Alzheimer's Disease.
  • the compounds of this invention are, in general, less toxic and have a broader therapeutic window than known compounds such as tacrine and physotigmine, making them therapeutically preferred.
  • the dosage of the compounds of the present invention will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular subject as well as the age, weight and condition of the subject under treatment as well as with the nature and extent of the symptoms. Generally, however, a dose in the range of about 1 to about 300 mg/day, taken in single or divided doses, will be administered. The preferred dose is in the range of from about 1 to about 150 mg/day in single or divided doses.
  • treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • the compounds of the present invention are used alone or in combination with pharmacologically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard medical practice. For example, they are administered orally in the form of capsules, tablets, suspensions or solutions or they may be injected parenterally. Capsules and tablets are the preferred mode of administration. For parenteral administration, they can be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
  • Capsule and tablet compositions may contain the active ingredient in admixture with one or more pharmaceutical excipients suitable for the manufacture of capsules and tablets.
  • suitable pharmaceutical excipients are, for example, starch, milk sugar, and certain types of clay.
  • the tablets can be uncoated or they can be coated by known techniques so as to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • Aqueous suspensions of the compounds of formula I contain the active ingredient in admixture with one or more pharmaceutical excipients suitable for the manufacture of aqueous suspensions.
  • suitable. excipients are, for example, methylcellulose, sodium alginate, gum acacia, lecithin and so forth.
  • Aqueous suspensions can also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
  • Non-aqueous suspensions can be formulated by suspending the active ingredient in a vegetable oil for example, arachis oil, olive oil, sesame oil, or coconut oil, or in mineral oil, for example liquid paraffin, and the suspension may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. These compositions can also contain a sweetening agent, flavoring agent and antioxidant.
  • Example 1 9-Amino-1,2,3,4-tetrahydro-1,4-methanoacridine
  • Anthranilonitrile 3.6 g, 30.0 mmole
  • norcamphor 3.3 g, 30.0 mmole
  • para-toluenesulfonic acid 50 mg
  • the reaction mixture was then cooled (25°C) and the separated water (about 1.5 ml) was withdrawn.
  • the excess benzene was then removed under vacuum (1 mm Hg, 15 minutes).
  • Example 2 9-Amino-8-fluoro-1 , 2 , 3 , 4-tetrahydro-1 , 4-methanoacridine Following the procedure of Example 1 , but substituting 2-amino-6-fluorobenzonitrile for anthranilo nitrile, afforded the title compound (23%, m.p. 173°C).
  • 1 N-NMR (CDCl 3 , 300 MHz , ⁇ ) 2H, m, 1.28-1.5 ppm; 1H, bd, 1.68 ppm; 1H, bd, 1.89 ppm; 2H, m, 1.98-2.18 ppm;
  • reaction mixture was cooled (25°C), was quenched with aqueous sodium hydroxide (70 ml) and was extracted with methylene chloride (4 x 60 ml). The combined organic phases were washed with water (2 x 100 ml) and dried (anhydrous MgSO 4 ). The organic solvents were removed under vacuum to yield a yellow residue which was loaded on a silica gel flash chromatography column. Elution with 5% methanol in methylene chloride afforded the title compound as yellow crystals (155 mg, 31%, m.p.
  • Example 6 9-Amino-2-thia-1,2,3,4-tetrahydroacridine Anthranilonitrile (2.6 g, 21.5 mmole), tetrahydrothiopyran-4-one (5.0 g, 43 mmole) and zinc chloride (2.54 g, 21.5 mmole) were combined and heated to 120°C for 20 minutes. The reaction mixture was cooled and the solid residue was filtered using ethyl ether (100 ml). The resulting orange solid (5.2 g) was placed in a beaker containing a saturated solution of EDTA (ethylene diamine tetracetic acid) in water (125 ml) and the pH was adjusted to 13 with the help of 12% NaOH.
  • EDTA ethylene diamine tetracetic acid
  • reaction mixture was treated with 25% aqueous NaOH (40 ml) and methylene chloride (100 ml) and was filtered through a 2 inch diatomaceous earth pad (Celite (trademark)) which was washed with methylene chloride (50 ml) and water (100 ml). The organic layer was separated, washed once with water (30 ml) and dried (anhydrous MgSO 4 ). The methylene chloride was removed under vacuum to afford an oil which was triturated with ether to give the title compound as a white solid (565 mg, 28%).
  • Example 8 9-Amino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine Following the procedure of Example 7, but substituting 2-amino-6-fluorobenzonitrile for anthranilonitrile afforded the title compound (8%, m.p. 195-196°C) .
  • Example 9 9-Amino-7-chloro-4-oxa-1,2,3,4-tetrahydroacridine Following the procedure of Example 7, but substituting 2-amino-5-chlorobenzonitrile for anthranilonitrile afforded the title compound (2%, m.p. 278-279 °C) .
  • Example 10 9-Amino-4-oxa-1,2,3,4,5-,6,7,8-octahydroacridine Following the method of Example 7, but substituting 2-amino-1-cyano-1-cyclohexene for anthranilonitrile. affcrded the title compound (8%, m.p. 145°).
  • Tetrahydrophiophen-3-one (1 ml) and titanium (IV) chloride (1.0 ml) was then added to the reaction mixture and the mixture was stirred at 25°C for 16 hours. Thereafter, the reaction mixture was quenched with 12% aqueous NaOH (100 ml) and the reaction mixture was then stirred vigorously with additional methylene chloride (300 ml). The reaction mixture was then filtered through diatomaceous earth (Celite
  • Example 13 9-Amino-1,2,3,4,5,6,7,8-octahydro-1,4-methanoacridine
  • norcamphor 0.9 g, 8.2 mmole
  • methylene chloride 8.0 ml
  • 2-amino-1-cyano-1-cyclohexene 1.0 g, 8.2 mmole
  • reaction mixture was then quenched with 12% aqueous NaCH ( 60 ml) and was stirred vigorously with methylene chloride (60 ml).
  • the reaction mixture was then filtered through a 2" pad of diatomaceous earth (Celite (trademark)). The organic phase was separated , washed with water ( 2 x 50 ml) and then dried (anhydrous MgSO 4 ) .
  • Methvlene chloride was then removed under reduced pressure to afford an oil which was triturated with pentane to give the title compound as a off-white solid (225 mg, 13%, m.p. 131-133°C).
  • Example 14 9-Amino-6-aza-1,2,3,4-tetrahydroacridine Titanium(IV) chloride (1.5 ml) was added to a stirred solution of 3-amino-4-cyano-pyridine (500 mg, 4.2 mmole) and cyclohexanone (0.5 ml) in 1,2-dichloroethane (15 ml). The reaction mixture was then maintained at 90°C for 12 hours. At the end of this period, cyclohexanone (2.0 ml) and 1,2-dichloroethane (5.0 ml) were added to the reaction mixture and the heating was continued for another 12 hours.
  • Example 15 9-Amino-5-aza-1,2,3,4-tetrahydroacridine Following the method of Example 14, but substituting 2-amino-3-cyano-pyridine for 3-amino-4-cyano-pyridine, afforded the title compound (38%, m.p. 225-228°C dec).
  • Example 19 9-Amino-6-aza-1,2,3,4-tetrahydro-1,4-methanoacridine Following the method of Example 16, but substituting norcamphor for delta-valerolactone and
  • Example 34 9-Methylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine Following the method Example 20, but substituting iodomethane for cyclohexylmethyl bromide afforded the title compound (for HCl salt:m.p. 240°C).
  • Example 36 9-Amino-1,2-dihyroacridine-4(32)-one Following the method of Example 1, but substituting 1,2-cyclohexanedione for norcamphor, afforded the title compound (11%, m.p. 240°C dec).
  • reaction mixture was treated with 12% aqueous NaOH (100 ml), and methylene chloride (100 ml).
  • the reaction mixture was then filtered through a 2 inch diatomaceous earth pad (Celite (trademark)) which was washed with methylene chloride (50 ml) and water (100 ml) .
  • the organic layer was separated, washed with water (1x30 ml) and dried (anhydrous MgSO 4 ).
  • the methylene chloride was removed under vacuum to afford an oil which was triturated with ether to give the title compound as a white solid (218 mg, 10%, m.p. 175°C).
  • Example 39 9-Amino-8-chloro-1,2,3,4-tetrahydroacridine Following the method of Example 37, but substituting 2-amino-6-chlorobenzonitrile for 2-amino-6-fluorobenzonitrile, afforded the title compound (23%, m.p. 144-145°C).
  • Example 40 4-Amino-5-fluoro-2,3-pentamethylenequinoline Following the method of Example 37, but substituting cvcloheptanone for cyclohexanone, afforded the title compound (22%, m.p. 203°C).
  • Example 41 4-Amino-5-chloro-2,3-pentamethylenequinoline Following the method of Example 37, but substituting cycloheptanone for cyclohexanone and 2-amino-6-chlorobenzonitrile for 2-Amino-6-fluorobenzonitrile, afforded the title compound (11%, m.p. 194-195 °C) .
  • 1 H-NMR (CDCl 3 , 300 MHz , ⁇ ) 1H , d , 7 .
  • Example 42 4-Amino-5-fluoro-2,3-trimethylenequinoline Following the method of Example 37, but substituting cyclopentanone for cyclohexanone, afforded the title compound (6%, m.p. 179-181°C).
  • Example 43 9-Amino-8-chloro-4-oxo-1,2,3,4-tetrahydro,cridine Following the method of Example 7, but substituting 2-amino-6-chlorobenzonitrile for anthranilonitrile, afforded 'the title compound (15%, m.p. 205°C).
  • Example 44 9-Amino-8-methyl-4-oxa-1,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting 2-amino-6-methylbenzonitrile for anthranilonitrile, afforded the title compound (20%, m.p. 177-179°C).
  • Example 47 The ability of the title compounds of Examples 1-16, 18, 26-29, and 35-46 to inhibit brain acetylcholinesterase was determined by the spectrophotometric method of G. L. Ellman et al. (Biochemical Pharmacology, 7 , 88 (1961)). All of the compounds had IC 50 (molar) values between 5 ⁇ M and 0.1 ⁇ M.

Abstract

Compounds of formula (I), wherein R1, R2, A and B are defined hereinbelow. The compounds of the present invention inhibit brain acetylcholinesterase and are useful in the treatment of Alzheimer's disease.

Description

4-AMINOPYRIDINE DERIVATIVES
Background of the Invention The present invention relates to 4-aminopyridine derivatives. The compounds of the present invention inhibit brain acetylcholinesterase and are useful in the treatment of Alzheimer's disease.
Tetrahydroaminoacridine, which has anticholinesterase activity, has been reported to produce improved performance in psychological tests in patients afflicted with Alzheimer's disease (W. K. Summers et al., The New England Journal of Medicine, 315, 1241-1245 (1986)). The anticholinesterase physostigmine has also been reportedly used in the experimental treatment of Alzheimer's disease (S. D. Brinkman et al., Neurobiol. Aging, 4, 139-145 (1983)).
The compounds described in the following four documents are alleged to have anticholinesterase activity:
United States Patent 4,652,567 refers to benzo(C)-1,5-naphthyridines for treating Alzheimer's disease.
United States Patent 4,631,286 refers to 9-amino-1,2,3,4-tetrahydroacridine-1-ol and related compounds for treating Alzheimer's disease. United States Patent 4,550,113 refers to 9-amino- 2,3,5,6,7,8-hexahydro-1H-cyclopenta (b) quinoline mono-hydrate hydrochloride for treating neuritis, injuries of the peripheral nervous system, hereditary neuromuscular diseases, and disseminated sclerosis. United States Patent 4,578,394 refers to dihydropyridines for treating Alzheimer's disease. United States Patent 4,540,564 refers to dihydropyridines for delivering drugs to the brain.
G. K. Patnaik et al., J. Med. Chem., 9 , 483-488 (1966), refer to 4-substituted 2,3-polymethylenequinolines having analgetic, local anesthetic, analeptic, and respiratory stimulant activities.
British Patent Specifications 1,186,061, 1,186,062, and 1,186,063 refer to benzonaphthyridine derivatives.
Summary of the Invention
The present invention relates to compounds of the formula
Figure imgf000004_0001
wherein A is selected from the group consisting of
an
Figure imgf000004_0008
d
Figure imgf000004_0007
Figure imgf000004_0002
Figure imgf000004_0003
Figure imgf000004_0004
Figure imgf000004_0005
Figure imgf000004_0006
wherein one of the CH moieties at positions a, b, c and d of formula 1 may be replaced by a nitrogen atom or each of the CH moieties at positions a and d, a and c or b and d may be replaced by a nitrogen atom; B is selected from the group consisting of
Figure imgf000005_0001
Figure imgf000005_0002
Figure imgf000005_0003
and
Figure imgf000005_0005
Figure imgf000005_0004
wherein each broken line represents an optional double bond; R1 is hydrogen or C1-C6 alkyl; R3 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, di(C1-C6 alkylamino)-C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl, halogen (e.g., fluoro, chloro, bromc or iodo), hydroxy, nitro, phenyl, substituted phenyl, phenyl-C1-C6 alkyl, substituted phenyl-C1-C6 alkyl, diphenyl-C1-C6 alkyl wherein one or both of the phenyl groups may be replaced with a substituted ohenyl group, furyl-C1-C6 alkyl, thienyl-C1-C6 alkyl, phenyloxy, substituted phenyloxy, NHCOR5 and NR6R7, wherein the phenyl moieties on the substituted phenyl and substituted phenylalkyl groups are substituted with one or more substituents
(preferably, one or two substituents) selected from the group consisting of halogen (e.g., fiuoro, chloro, bromo or iodo), C1-C6 alkyl, trifluoromethyl, C1-C6 alkoxy-C1-C6 alkyl, hydroxy and nitro, and wherein R5, R6 and R7 are independently selected from C1-C6 alkyl and C1-C6 alkanoyl; R2 is independently selected from the group consisting of 1,4-dihydropyridyl-C1-C6 alkanoyl, C1-C6 alkyl-1,4-dihydropyridyl-C1-C6-alkanoyl, and the possible definitions set forth above for R3, except that R2 cannot be hydroxy, halogen, C1-C6 alkoxy, phenyloxy or substituted phenyloxy; R4 is independently selected from the possible definitions set forth above for R 3, except that R4 cannot be halogen, nitro, NHCOR5 or NR6R7; n is 1, 2 or 3 ; Z1 is
NH, O, S or NR8 wherein R8 is C1-C6 alkyl or C1-C6 alkanoyl; Z1 is O or S; Z3 and Z4 are independently selected from (CH2)P, O, S, S=O and SO2, with the proviso that at least one of Z3 and Z4 is (CH2)P; Z5 is
CH2, O, S, S=O or SO2; Z6 is O, S, S=O or SO2; p is
1, 2 or 3; q is 1- or 2; Y1 is CH2, CHOH, O, C=O, S, S=O or SO2; Y2 is CH2, CH, O, S, S=O or SO2; and Y3 is
CHOH, CH2, CH or C=O, with the proviso that the group of the formula 8 may have a double bond only when both
Y 2 and Y3 are CH, with the proviso that when A is a group of the formula 1 wherein R3 is hydrogen and there is no nitrogen at position a, b, c or d or A is a group of the formula 3 or 4, only one of Y 1 and Y2 can be
CH2, and with the proviso that when A is a group of the formula 1 wherein R3 is hydrogen and there is no nitrogen at position a, b, c, or d, only one of Z3 and Z4 can be (CH 2)p ; and pharmaceutically acceptable salts thereof.
The present invention also relates to a pharmaceutical composition for the treatment of Alzheimer's disease comprising a compound of the formula I and to the use of compounds of the formula I in treating Alzheimer's disease. The present invention also relates to methods of preparing compounds of the formula I.
One embodiment of the present invention relates to compounds of the formula I wherein R 1, R2, A and B are as defined for formula I, with the proviso that when A is a group of the formula 1 wherein there is no nitrogen at position a, b, c or d or A is a group of the formula 3 or 4, only one of Y1 and Y2 can be CH2; and pharmaceutically acceptable salts thereof. One aspect of the foregoing embodiment relates to compounds wherein Y 3 is CH2, and at least one of Z3 and Z4 is
CH2; with the proviso that when A is a group of the formula 1 wherein R3 is hydrogen and there is no nitrogen at position a, b, c or d, only one of Z3 and
Z4 can be (CH2)P.
A preferred embodiment of the present invention relates to compounds of the formula I wherein A, B, Z1, Z2, Z3, Z4, Z5, Z6 and Y3 are as defined with respect to formula I; R 1, R2 and R4 are hydrogen; and R3 is hydrogen or halogen; with the proviso that when A is a group of the formula 1 wherein there is no nitrogen at position a,b,c or d, or A is a group of the formula 3 or 4, only one of Y1 and Y2 can be CH2; and pharmaceutically acceptable salts thereof. When R3 is halogen, the halogen is preferably fluorine.
Another preferred embodiment of the present invention relates to compounds of the formula I wherein A is a group of the formula 1, wherein one of the CH moieties at positions a and b of formula 1 may be replaced by a nitrogen atom, cr A is a group of the formula 3;
B, R1, R2, R3, R4, Z3, Z4, Z5, Y3 and q are as defined with respect to formula I; n is 1 or 2; Z6 is S; and p is 1 or 2; with the proviso that (a) when A is a group of the formula 1 wherein there is no nitrogen at either position a or position b , Z3 is O , S or CH2; R 4 is hydrogen or C1-C6 alkyl; Z4 is (CH2)P , wherein p is 1 or 2, or S; Y1 is CH2, C=O, O, or S, and Y2 is CH2, O or S, with the proviso that only one of Y 1 and Y2 can be CH2;
(b) when A is a group of the formula 1 wherein there is a nitrogen at either position a or position b, Y 1 is O, S or CH2 and Y2 is CH2; and
(c) when A is a group of the formula 3, Y1 is O or S; and Y2 is CH2; and the pharmaceutically acceptable salts thereof. In a more preferred embodiment, R 1, R2 and R4 are hydrogen and R 3 is hydrogen or halogen. When R3 is halogen, the halogen is preferably fluorine.
Another preferred embodiment of the present invention relates to compounds of the formula I, wherein B is a group of the formula 7 or 8 and A, R1,
R2, R3, Z1, Z2, q, Y1, Y2 and Y3 are as defined with respect to formula I, with the proviso that when A is a group of the formula 1 wherein there is no nitrogen at position a, b, c, cr d, or A is a group of the formula 3 or 4, only one of Y 1 and Y2 can be CH2; and pharmaceutically acceptable salts thereof. In a mere preferred embodiment, R 1 and R2 are hydrogen and R3 is hydrogen or halogen. When R3 is halogen, the halogen is preferably fluorine. A particularly preferred embodiment of the present invention relates to compounds of the formula Z , wherein A is a group of the formula 1, wherein one of the CH moieties at positions a and b of formula 1 may be replaced by a nitroqen atom, or A is a group of the rormula 3; B is a group of the formula 7 or 8; R 1, R2, R3, q, Y1 , Y2 and Y3 are as defined for formula I; and n is 1 or 2; with the proviso that
(a) when A is a group of the formula 1 wherein there is no nitrogen at either position a or position b, Y 1 is CH2, C=O, O or S, and Y 2 is CH2, O or S, with the proviso that only one of Y 1 and Y 2 can be CH2;
(b) when A is a group of the formula 1 wherein there is a nitrogen at either position a or position b, Y 1 is O, S or CH2 and Y2 is CH2; and
(c) when A is a group of the formula 3, Y 1 is O or S; and Y 2 is CH2; and the pharmaceutically acceptable salts thereof. In a more preferred embodiment, R 1, R2 and R4 are hydrogen and R 3 is hydrogen or halogen. When R3 is halogen, the halogen is preferably fluorine.
Another preferred embodiment of the present invention relates to compounds of the formula I, wherein A is a group of the formula 1, wherein R3 is as defined for formula I, with the proviso that R3 may only be at position d of formula 1, and R1, R2 and B are as defined for formula I, and the pharmaceutically acceptable salts thereof. In a more preferred embodiment, R3 is halogen, more preferably, fluorine.
Another preferred embodiment of the present invention relates to compounds of the formula I, wherein A is a group of the formula 1, wherein R3 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, nitro, NHCOR5 ,NR6R7 or trifluoromethyl; B is a group of the formula
Figure imgf000009_0001
wherein r is 2,3 or 4; and R1,R2,R5,R6 and R7 are as defined for formula I; and the pharmaceutically acceptable salts thereof. Of the foregoing compounds the more preferred compounds are those wherein R3 is at the d position of formula 1 or wherein R3 is halogen.
Particularly preferred compounds are those wherein R3 is halogen at the d position. When R3 is halogen, the halogen is preferably fluorine. Specific preferred compounds of the present invention are the following:
9-amino-4-oxa-1,2,3,4-tetrahydroacridine;
9-amino-1,2,3,4-tetrahydro-1,4-methanoacridine;
9-amino-8-fluoro-1,2,3,4-tetrahydro-1,4-methanoacridine;
9-amino-2-oxa-1,2,3,4,-tetrahydroacridine;
9-amino-2-thia-1,2,3,4-tetrahydroacridine;
9-amino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine;
9-amino-4-oxa-1,2,3,4,5,6,7,8-octahydroacridine; 2,3-dihydrothieno[3,2-b]quinoline-9-amine;
9-amino-5-aza-1,2,3,4-tetrahydroacridine;
2, 3-dihydro-8-fluoro-thieno[3,2-b]quinolin-9-amine;
9-amino-1,2-dihydroacridine-4(3H)-one;
1,3-dihydro-8-fluoro-thieno[3,4-b]quinolin-9-amine; 9-amino-4-thia-1,2,3,4-tetrahydroacridine;
8-fluoro-9-amino-1,2,3,4-tetrahydroacridine; and
9-amino-8-fluoro-2-thia-1,2,3,4-tetrahydroacridine.
Other compounds of the present invention are the following: 9-amino-4,5-thiaza-1,2,3,4-tetrahydroacridine;
9-amino-4-thia-1,2,3,4,5,6,7,8-octahydroacridine;
9-amino-2-thia-1,2,3,4,5,6,7,8-octahydroacridine;
9-amino-2-oxa-1,2,3,4,5,6,7,8-octahydroacridine;
9-amino-5,7-diaza-1,2,3,4-tetrahydroacridine; 9-amino-3-methyl-7-phenyl-4-oxa-1,2,3,4-tetrahydroacridine;
9-amino-6-trifluoromethyl-1,4-methano-1,2,3,4-tetrahydroacridine;
9-amino-5,8-diaza-1,4-methano-1,2,3,4-tetrahydroacridine; 9-amino-1-thia-1,2,3,4-tetrahydroacridine;
9-amino-3-thia-1,2,3,4-tetrahydroaσridine;
4-amino-5,6,7,8-tetrahydro-1H-imidazo[4,5-b]-quinoline;
4-amino-5,6,7,8-tetrahydro-oxazolo[4,5-b]quinoline;
4-amino-5,6,7,8-tetrahydro-thiazolo[4,5-b]quinoline;
9-amino-1,2,3,4-tetrahydroacridine-4-ol;
9-amino-6-trifluoromethyl-4-oxa-1,2,3,4-tetrahydroacridine;
9-amino-6-trifluoromethyl-1-hydroxy-4-oxa-1,2,3,4-tetrahydroacridine; and
9-amino-1-hydroxy-4-oxa-1,2,3,4-tetrahydroacridine.
Preferred compositions of the present invention contain the foregoing preferred compounds. More preferred compositions of the present invention contain the foregoing more preferred compounds and specific preferred compounds.
Detailed Description of the Invention
Compounds of the present invention may be prepared as described below.
Figure imgf000011_0001
As shown in Scheme I, an aminonitrile of the formula II, wherein A is as defined above, is reacted with a ketone of the formula III wherein B is as defined above to prepare a ketimine of the formula IV. The reaction is conducted in an inert solvent, preferably an aromatic solvent (e.g., benzene or toluene), in the presence of an acid, preferably a strong acid (e.g. p-toluenesulfonic acid). The temperature should be at least about 100°C, but is otherwise not critical. Generally, the reaction is conducted at the reflux temperature of the reaction mixture, e.g., by refluxing the reaction mixture in a Dean Stark apparatus, preferably for about 6 to about 16 hours, and removing the water periodically. The reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere).
The crude ketimine IV obtained after the removal of solvent is then reacted with a base (e.g., lithium diisopropylamide) in. an inert solvent, preferably an anhydrous ether (e.g., tetrahydrofuran), at a temperature of about 0°C to about 25°C. The reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere).
The first method works especially well when an ail carbon ketone is employed in the reaction. Azeotropic removal (80°C, PTSA, 15 hours) of water from a benzene solution of norcamphor (or an ail carbcr. ketone) and anthranilonitrile afforded the corresponding ketimine which on treatment with lithium diisopropylamide (0°C, 4 hours) in tetrahydrofuran afforded the compound of Example 1 in 25% yield. The use of this procedure is also exemplified by the preparation of the compounds of Examples 2, 3, 4, 30 and 36.
The limitation in the general applicability of the first method is the difficulty of formation of ketimines from carbonyl compounds containing a nitrogen or oxygen atom. Titanium (IV) chloride, because of its high affinity for oxygen, has been used in the preparation of ketimines. (See H. Weingarten et al., J. Org. Chem., 32, 3246(1967)). This observation was adapted for the synthesis of 9-amino-1,2,3,4-tetrahydroacridine derivatives in a single step by the condensation of appropriate o-aminonitriles with diverse carbonyl components.
Thus, in a second method for preparing compounds of the present invention, a compound of the formula II wherein A is defined as above is reacted with a carbonyl-containing compound of the formula III wherein B is as defined above. The carbonyl-containing compound may be a. ketone, a lactone, or the like. The reaction is conducted in an inert solvent in the presence of a Lewis acid (e.g., titanium (IV) chloride) and, if necessary, in the presence of a base, preferably an amine base (e.g. triethylamine). Suitable solvents include aromatic solvents (e.g., benzene cr toluene) and chlorinated solvents (e.g., methylene chloride or 1,2-dichloroethane). The reaction temperature should be at least about 0°C and is preferably about 25 to about 120°C. The reaction pressure is not critical. Generally, the reaction will be conducted at a pressure of about 0.5 to about 2 atmospheres, preferably at ambient pressure (generally, about 1 atmosphere).
Thus, for example, condensation of deltavalerolactone with anthranilonitrile in methylene chloride by titanium (IV) chloride at 25°C in the presence of triethylamine (2 equivalents) afforded the compound of Example 7 (28%). This method was adopted for the synthesis of the compounds of Examples 7-19, 26-29, 31-33, 35 and 37-46. The compounds of Examples 5 and 6 were prepared by condensing anthranilonitrile with the appropriate ketones in the presence of anhydrous zinc chloride at elevated temperature (<140°C).
Monoalkylation of the amine group in compounds of the present invention may be achieved by heating them with appropriate alkyl halides in the presence of sodium hydride in dimethylformamide. This is exemplified by the synthesis of the compounds of Examples 20-25 and 34.
The compounds of Formula I are capable of forming acid addition salts with pharmaceutically acceptable acids. The acid addition salts may be prepared by reacting the base form of the appropriate compound of formula I with one or more equivalents, preferably with an excess, of the appropriate acid in an organic solvent, for example, diethyl ether or an ethanol diethyl ether mixture. Suitable acids to form these salts include the common mineral acids, e.g. hydrohalic, sulfuric or phosphoric acid; the organic acids, e.g. ascorbic, citric, lactic, aspartic or tartaric acid or their aqueous solutions whose pH has been adjusted to 5.5 or less; and acids which are sparingly soluble in body fluids and which impart slow-release properties to their respective salts, e.g. pamoic or tannic acid or carboxymethyl cellulose. The preferred salt is the hydrochloride salt.
The compounds of formula I and the pharmaceutically acceptable salts thereof are useful in the treatment of various memory dysfunctions associated with decreased cholinergic function such as Alzheimer's Disease. Additionally, the compounds lead to stimula tion of neuromuscular transmission, enhancement of excitation in excitable tissues (nerve, and smooth and striated muscle) as well as restoration of conductance in nerves, and neuromuscular synapses in the case of injury thereof. The compounds of this invention also exhibit antidepressant activities which is particularly helpful for patients suffering from Alzheimer's Disease. The compounds of this invention are, in general, less toxic and have a broader therapeutic window than known compounds such as tacrine and physotigmine, making them therapeutically preferred.
In treating Alzheimer's disease, the dosage of the compounds of the present invention will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular subject as well as the age, weight and condition of the subject under treatment as well as with the nature and extent of the symptoms. Generally, however, a dose in the range of about 1 to about 300 mg/day, taken in single or divided doses, will be administered. The preferred dose is in the range of from about 1 to about 150 mg/day in single or divided doses.
Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
The compounds of the present invention are used alone or in combination with pharmacologically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard medical practice. For example, they are administered orally in the form of capsules, tablets, suspensions or solutions or they may be injected parenterally. Capsules and tablets are the preferred mode of administration. For parenteral administration, they can be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
Capsule and tablet compositions may contain the active ingredient in admixture with one or more pharmaceutical excipients suitable for the manufacture of capsules and tablets. Suitable pharmaceutical excipients are, for example, starch, milk sugar, and certain types of clay. The tablets can be uncoated or they can be coated by known techniques so as to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
Aqueous suspensions of the compounds of formula I contain the active ingredient in admixture with one or more pharmaceutical excipients suitable for the manufacture of aqueous suspensions. Suitable. excipients are, for example, methylcellulose, sodium alginate, gum acacia, lecithin and so forth. Aqueous suspensions can also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents. Non-aqueous suspensions can be formulated by suspending the active ingredient in a vegetable oil for example, arachis oil, olive oil, sesame oil, or coconut oil, or in mineral oil, for example liquid paraffin, and the suspension may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. These compositions can also contain a sweetening agent, flavoring agent and antioxidant.
The following examples illustrate the preparation and properties of the compounds of the present invention. All melting points are uncorrected. Thin layer chromatography (TLC) was conducted on silica gel.
Example 1 9-Amino-1,2,3,4-tetrahydro-1,4-methanoacridine A solution of anthranilonitrile (3.6 g, 30.0 mmole), norcamphor (3.3 g, 30.0 mmole) and para-toluenesulfonic acid (50 mg) in benzene (50 ml) was heated to reflux using a Dean Stark apparatus. After heating for 18 hours, the reaction mixture was then cooled (25°C) and the separated water (about 1.5 ml) was withdrawn. The excess benzene was then removed under vacuum (1 mm Hg, 15 minutes). The oily residue thus obtained was dissolved in tetrahydrofuran (THF, 10 ml) and was cooled to 0°C and a solution of lithium diisopropylamide in THF (1M, 36 ml, 36 mmole) was then added. This reaction mixture was then stirred at 0°C for 3 hours. At the end of this period , the reaction mixture was quenched with 40 ml of water and was extracted with methylene chloride (200 ml). The resulting organic phase was washed with water (2 x 50 ml) and dried (anhydrous MgSO4) . The methylene chloride was removed under vaccum to afford a residue which was loaded on a silica gel flash chromatography column. Elution with 5% methanol in methylene chloride containing 1% triethylamine afforded the title compound 1.6 g, 25%) as an oil which solidified on standing
(m.p. 185-186°C). 1H-NMR (CDCl3, 300 MHz, δ): 2H, m, 1.22-1.42 ppm; 1H, d, 1.64 ppm (J = 7.0 Hz); 1H, d, 1.86 ppm (J = 6.0 Hz); 2H, m, 1.9-2.04 ppm; 2H , bd, 3.46 ppm; 2H , bs, 4.49 ppm; 1H, t, 7.38 ppm (J = 6.0 Hz); 1H, t, 7.55 ppm (J = 6.0 Hz); 1H, d, 7.67 ppm (J = 6.0 Hz); 1H, d, 7.92 ppm (J = 6.0 Hz).
Example 2 9-Amino-8-fluoro-1 , 2 , 3 , 4-tetrahydro-1 , 4-methanoacridine Following the procedure of Example 1 , but substituting 2-amino-6-fluorobenzonitrile for anthranilo nitrile, afforded the title compound (23%, m.p. 173°C).1N-NMR (CDCl3, 300 MHz , δ ) : 2H, m, 1.28-1.5 ppm; 1H, bd, 1.68 ppm; 1H, bd, 1.89 ppm; 2H, m, 1.98-2.18 ppm;
2H, bs, 3.5 ppm; 2H, bs, 5.18 ppm; 1H, dd, 7.0 ppm (J = 12.5, 8.0 Hz); 1H, m, 7.44 ppm (J = 12.5, 8.0 HZ); 1H, d, 7.75 ppm (J = 8.0 Hz).
HRMS: Calculated - 228.1062; Found - 228.1049.
TLC: (90:10:1-methylene chloride:methanol: 28% aqueous ammonia) Rf = 0.7. Example 3
9-Amino-7-chloro-1,2,3,4-tetrahydro-1,4-methanoacridine Following the procedure of Example 1, but substituting 2-amino-5-chlorobenzonitrile for anthranilonitrile, afforded the title compound (14%, m.p. 183-184°C). 1H-NMR (CDCl3 , 300 MHz, δ): 2H, m,
1.3-1.56 ppm; 1H, bd, 1.65 ppm; 1H, bd, 1.92 ppm; 2H, m, 1.98-2.18 ppm; 1H, bs, 3.5 ppm; 1H, bs, 3.54 ppm;
2H, bs, 4.45 ppm; 1H, dd, 7.5 ppm (J = 2, 9.0 Hz); Ih, d, 7.65 ppm (J = 2 Hz); 1H, d, 7.84 ppm (J = 9.0 Hz). HRMS: Calculated - 244.0767; Found - 244.0750.
TLC: (90:10:1-methylene chloride:methanol: 28% aqueous ammonia) Rf = 0.7.
Example 4
9-Amino-1,4-dihydro-1,4-methanoacridine Following the procedure of Example 1 , but substituting 5-norbornen-2-one for norcamphor, afforded the title compound (26%, m.p. 123°C) . 1H-NMR (CDCl3,
300 MHz, δ ) : 1H, d, 2.4 ppm (J = 8.0 Hz) , 1H, dt, 2.5 ppm (J = 1.7, 8.0 Hz); 1H, bs, 3.88 ppm; 1H, bs, 4.07 ppm; 1H, bs , 4.46 ppm, 2H, s, 6.86 ppm; 1H, t, 7.44 ppm
(J = 8.0 Hz); 1H, t, 7.6 ppm (J = 8.0 Hz); 1H, d, 7.68 ppm (J = 8.0 Hz); 1H, d, 7.94 ppm (J = 8.0 Hz) .
HRMS: Calculated - 208.2622; Found - 208.0974.
TLC:(90:10:1-methy-ene chloride:methanol: 28% aqueous ammonia) Rf = 0.57. Example 5 9-Amino-2-oxa-1,2,3,4-tetrahydroacridine Anthranilonitrile (25 mmole, 2.95 g) , zinc chloride (3.1 g, 25 mmole) and tetrahydro-4H-pyran-4-one were dissolved in toluene (40 ml) and heated to reflux for 2.5 days. At the end of this period, the reaction mixture was cooled (25°C), was quenched with aqueous sodium hydroxide (70 ml) and was extracted with methylene chloride (4 x 60 ml). The combined organic phases were washed with water (2 x 100 ml) and dried (anhydrous MgSO4). The organic solvents were removed under vacuum to yield a yellow residue which was loaded on a silica gel flash chromatography column. Elution with 5% methanol in methylene chloride afforded the title compound as yellow crystals (155 mg, 31%, m.p.
195-196°C). 1H-NMR (CDCl3, 300 MHz, δ): 2H, t, 3.08 ppm (J = 6.0 Hz); 2H, t, 4.06 ppm (J = 6.0 Hz); 2H, bs, 4.47 ppm; 2H, s, 4.74 ppm; 1H, t, 7.34 (J = 8.0 Hz); 1H, t, 7.54 (J = 8.0 Hz); 1H, d, 7.64 (J = 8.0 Hz); 1H, d, 7.84 (J - 8.0 Hz). TLC: (TLC plate pretreated with 2% triethylamine in hexane; eluant: 5% methanol in methylene chloride) Rf = 0.25.
Example 6 9-Amino-2-thia-1,2,3,4-tetrahydroacridine Anthranilonitrile (2.6 g, 21.5 mmole), tetrahydrothiopyran-4-one (5.0 g, 43 mmole) and zinc chloride (2.54 g, 21.5 mmole) were combined and heated to 120°C for 20 minutes. The reaction mixture was cooled and the solid residue was filtered using ethyl ether (100 ml). The resulting orange solid (5.2 g) was placed in a beaker containing a saturated solution of EDTA (ethylene diamine tetracetic acid) in water (125 ml) and the pH was adjusted to 13 with the help of 12% NaOH. The aqueous phase was then extracted with methylene chloride (4 x 50 ml) which was washed with water (2 x 70 ml) and dried (MgSO4). Removal of methylene chloride under vacuum afforded a yellow paste (2.0 g) which was triturated with ether and filtered to afford a light yellow solid (1.36 g, 29%, m.p. 205°C dec). 1H-NMR (CDCl3, 300 MHz , δ ) : 2H, 5, 3.0 ppm (J = 6.0 Hz); 2H, t, 3.35 ppm (J = 6.0 Hz) ; 2H, s, 3.72 ppm; 2H, bs, 4.69 ppm; 1H, t, 7.4 (J = 8.0 Hz); 1H, t, 7.6 (J = 8.0 Hz); 1H, d, 7.69 (J = 8.0 Hz); 1H, d, 7.88 (J = 8.0 Hz). HRMS: Calculated - 216.0719; Found - 216.0688. TLC: (TLC plate pretreated with 2% triethylamine in hexane; eluant: 5% methanol in methylenechloride) Rf = 0.23.
Example 7 9-Amino-4-oxa-1,2,3,4-tetrahydroacridine To a stirred solution of delta-valerolactone
1.0 g, 10.0 mmole) in methylene chloride (10 ml) at -20°C, a IM solution of titanium(IV) chloride in methylene chloride (20 ml) was added. The reaction mixture became dark yellow in color and to it a mixture of triethylamine (2.0 g, 20 mmole) and anthranilonitrile (1.2 g, 10.0 mmlole) in methylene chloride (30 ml) were added. The reaction mixture immediately became dark in color and was allowed to warm to room temperature (about 25°C) and stirred further for 15 hours. At the end of this period, the reaction mixture was treated with 25% aqueous NaOH (40 ml) and methylene chloride (100 ml) and was filtered through a 2 inch diatomaceous earth pad (Celite (trademark)) which was washed with methylene chloride (50 ml) and water (100 ml). The organic layer was separated, washed once with water (30 ml) and dried (anhydrous MgSO4). The methylene chloride was removed under vacuum to afford an oil which was triturated with ether to give the title compound as a white solid (565 mg, 28%). 1H-NMR (CDCl3, 300 MHz , δ ) : 2H, m, 2.02-2.18 ppm; 2H, t, 2.63 ppm (J = .6.0 Hz); 2H, t, 4.36 ppm (J = 6.0 Hz); 2H, s, 4.64 ppm; 1H, t,.7.25 (J = 8.0 Hz); 1H, t, 7.5 (J = 8.0 Hz); 1H, d, 7.72 (J = 8.0 Hz). HRMS: Calculated - 200.2396; Found - 200.0945. Analysis: Calculated for C12H12N2O : 71.98%C; 6.04%H;
13.99%N. Found: 70.91%C; 6.01%H; 14.19%N. TLC: (90:10:-1-methylene chloride:methanol:28% aqueous ammonia) Rf = 0.45.
Example 8 9-Amino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine Following the procedure of Example 7, but substituting 2-amino-6-fluorobenzonitrile for anthranilonitrile afforded the title compound (8%, m.p. 195-196°C) . 1H-NMR (CDCl3, 300 MHz , δ ) : 2H, m, 2.06-2.2 ppm; 2H, t, 2.6 ppm (J = 6.0 Hz); 2H, t, 4.37 ppm (J = 6.0 Hz); 2H, bs, 5.4 ppm; 1H, dd, 6.88 (J = 14.0,7.5 Hz); 1H, m, 7.3-7.44; 1H, d, 7.56 (J = 8.6 Hz). HRMS: Calculated - 218.0801; Found - 218.0284 TLC: (90:10:1-methylene chloride:methanol: 28% aqueous ammonia) Rf = 0.7.
Example 9 9-Amino-7-chloro-4-oxa-1,2,3,4-tetrahydroacridine Following the procedure of Example 7, but substituting 2-amino-5-chlorobenzonitrile for anthranilonitrile afforded the title compound (2%, m.p. 278-279 °C) . 1H-NMR (CDCl3 , 300 MHz , δ ) : 2H , m, 2 . 06-2 . 2 ppm; 2H, 5, 2.66 ppm (J = 6.0 Hz); 2H, t, 4.37 ppm (J = 6.0 Hz); 2H, bs , 4.61 ppm; 1H, dd, 7.45 (J = 9.0, 1.0 Hz); 1H, bs, 7.58 ppm (J = 1 Hz); 1H, d, 7.66 (J = 9.0 Hz). HRMS: Calculated - 234.056? Found -
234.0566. TLC: (90:10:1-methylene chloride methanol:28% aqueous ammonia) Rf = 0.6.
Example 10 9-Amino-4-oxa-1,2,3,4,5-,6,7,8-octahydroacridine Following the method of Example 7, but substituting 2-amino-1-cyano-1-cyclohexene for anthranilonitrile. affcrded the title compound (8%, m.p. 145°). 1Η-NMR (CDCl3 300 MHz, δ ) : 4H, m, 1.65-1.9 ppm; 2H, q, 2.07 ppm (J = 6.0 HZ) ; 2H, t, 2.4 ppm (J = 6.0 Hz); 2H, t, 2.5 ppm (J = 6.0 Hz); 2H, t, 2.76 ppm (J = 6.0 Hz); 4H, bt, 4.26 ppm. HRMS: Calculated - 204.2712; Found - 204.1227. TLC: (90:10:1-methylene chloride:methanol:23% aqueous ammonia) Rf = 0.46. Example 11
9-Amino-2,3,7,8-tetrahydro-1H-cyclopenta[e]5H-pyrano- [2'3'-b] pyridine
Following the method of Example 7, but substituting 2-amino-1-cyano-1-cyclopentene for anthranilonitrile, afforded the title compound (22%, m.p. 164°C). 1H-NMR (CDCl3 300 MHz , δ ) : 4H, m, 2.0-2.2 ppm; 2H, t, 2.48 ppm (J = 6.0 Hz); 2H, t, 2.68 ppm (J = 6.0 Hz); 2H, t, 2.87 ppm (J = 6.0 Hz); 2H, bs, 4.06 ppm (J = 6.0 Hz); 2H, t, 4.24 ppm. HRMS: Calculated - 190.1107; Found - 190.1107.
TLC:(90:10:1-methylene chloride methanol: 2S% aqueous ammonia) Rf = 0.86.
Example 12 2,3-Dihydrothieno[3,2-b;quinolin-9-amine To a stirred solution of tetrahydrothiophen-3-one
(1.1 g, 11 mmole) in methylene chloride (10 ml) at -78°C, a 1M solution of titanium(IV) chloride in metnviene cnicride (11,ml) was added. A mixture of triethylamine (2.2 g, 22 mmcie) and anthranilonitrile (1.2 gms, 10.0 mmole) in methylene chloride (30 ml; was then added to the reaction mixture over a period of 5 minutes. The reaction mixture was then slowly warmed to room temperature and stirred for 2 hours. Tetrahydrophiophen-3-one (1 ml) and titanium (IV) chloride (1.0 ml) was then added to the reaction mixture and the mixture was stirred at 25°C for 16 hours. Thereafter, the reaction mixture was quenched with 12% aqueous NaOH (100 ml) and the reaction mixture was then stirred vigorously with additional methylene chloride (300 ml). The reaction mixture was then filtered through diatomaceous earth (Celite
(trademark)) and the organic phase was separated. The organic solvents were removed under vacuum to afford a residue which was loaded on a flash chromatography column. Elution with 5% methanol in methylene chloride containing 1% triethylamine, afforded the title compound (1.3 gms, 64%) which was crystallized from chloroform (560 mg, 32%, m.p. 208-210°C). 1H-NMR
(CDCl3, 300 MHz, δ): 4H, m, 3.4-3.56 ppm; 2H, bs, 4.51 ppm; 1H, dt, 7.37 ppm (J = 7.0, 1.0 Hz); 1H, dt, 7.52 ppm (J = 7.0, 1.10 ppm); 1H, dd, 7.61 ppm (J = 7.0, 1.0 ppm); 1H, dd, 7.61 ppm (J = 7.0, 1.0 ppm), 1H, dd, 7.86 ppm (J = 7.0, 1.0 ppm). HRMS: Calculated - 202.0575;
Found - 202.0545. Analysis: Calculated for C11H10N2S: 65.32%C; 4.98%H; 13.85%N; 15.85%S. Found: 65.06%C; 5.00%H; 13.79%N; 15.63%S.
Example 13 9-Amino-1,2,3,4,5,6,7,8-octahydro-1,4-methanoacridine To a stirred solution of norcamphor (0.9 g, 8.2 mmole) in methylene chloride (8.0 ml) at -20°C, a mixture of triethylamine (1.7 g, 16.4 mmole) and 2-amino-1-cyano-1-cyclohexene (1.0 g, 8.2 mmole) in methylene chloride (24 ml) was added and the resulting mixture was stirred at 25°C for 15 hours. The reaction mixture was then quenched with 12% aqueous NaCH ( 60 ml) and was stirred vigorously with methylene chloride (60 ml). The reaction mixture was then filtered through a 2" pad of diatomaceous earth (Celite (trademark)). The organic phase was separated , washed with water ( 2 x 50 ml) and then dried (anhydrous MgSO4) . Methvlene chloride was then removed under reduced pressure to afford an oil which was triturated with pentane to give the title compound as a off-white solid (225 mg, 13%, m.p. 131-133°C). 1H-NMR (CDCl3 , 300 MHz , δ ) : 2H, m, 1.15-2.38 ppm; 1H, d, 1.5 ppm; 7H, m, 165-2.0 ppm; 2H, bs, 2.4 ppm; 2H, bd, 2.8 ppm; 2H, bd 3.3 ppm; 2H, s, ppm. HRMS: Calculated - 214.3096; Found - 1466. TLC: (90:10:1-methylene chloride: anol: 28% aqueous ammonia) Rf = 0.25
Example 14 9-Amino-6-aza-1,2,3,4-tetrahydroacridine Titanium(IV) chloride (1.5 ml) was added to a stirred solution of 3-amino-4-cyano-pyridine (500 mg, 4.2 mmole) and cyclohexanone (0.5 ml) in 1,2-dichloroethane (15 ml). The reaction mixture was then maintained at 90°C for 12 hours. At the end of this period, cyclohexanone (2.0 ml) and 1,2-dichloroethane (5.0 ml) were added to the reaction mixture and the heating was continued for another 12 hours. Additional cyclohexanone (2.0 ml) and titanium tetrachloride (1.2 ml) were then added and the reaction mixture was maintained at 90°C for 6 hours. The reaction mixture was then cooled and was quenched with 5% aqueous NaOH (250 ml) and was stirred vigorously with methylene chloride (200 ml, 25 minutes). The reaction mixture was then treated as in Example 8 to afford the title compound (170 mg, 95% pure, 20%) after flash chromatography on silica gel (eluant: 95:5:1; methylene chloride: methanol: ammonium hydroxide. This material was further purified by chromatography to afford the title compound (75 mg, m.p. 180-181°C) . 1 H-NMR (CDCl3 + CD3 OD, 300 MHz, δ ) : 4H, m, 1.9 ppm; 2H, bt, 2.54 ppm; 2H, s, 2.9 ppm; 2H, bt, 2.94 ppm; 1H, d, 7.52 ppm (J = 6.0 HZ) ; 1H, d, 8.24 ppm (J = 6.0 Hz) ; 1H, s, 9.06 ppm. HRMS: Calculated - 199.1109; Found - 199.1079. Example 15 9-Amino-5-aza-1,2,3,4-tetrahydroacridine Following the method of Example 14, but substituting 2-amino-3-cyano-pyridine for 3-amino-4-cyano-pyridine, afforded the title compound (38%, m.p. 225-228°C dec). 1H-NMR (CDCl3+CD3OD, 300 MHz , δ): 4H, bs, 1.86 ppm; 2H, bt, 2.5 ppm; 2H, bt, 2.97 ppm; 2H, vbs, 3.0-3.3 ppm; 1H, dd, 7.2 ppm (J = 8.0, 4.0 Hz); 1H, dd, 8.18 ppm (J = 8.0, 1-2 Hz); 1H, dd, 8.77 ppm (J = 4.0, 1-2 Hz). HRMS: Calculated - 199.1109; Found - 199.1102.
Example 16 9-Amino-4,5-oxaza-1,2,3,4-tetrahydroacridine To a stirred solution of 2-amino-3-cyano-pyridine (360 mg, 3.0 mmole) and delta-valerolactone (360 mg,
3.6 mmole) in 1,2-dichloroethane (7.0 ml), titanium(IV) chloride (0.9 ml) was added and then the reaction mixture was maintained at 90°C for 18 hours. The reaction mixture was then quenched with 15% aqueous NaOH (200 ml) and was stirred vigorously with methylene chloride (200 ml, 25 minutes). The reaction mixture was then worked up as in example 15 to afford the title compound (8%, m.p. 269-270°C dec). 1H-NMR (CDCl3+CD3OD, 300 MHz, δ ): 2H , q, 2.04 ppm (J = 6.5 Hz); 2H, t, 2.57 ppm (J = 6.5 ppm); 2H, bs, 3.76 ppm; 2H, t, 4.28 ppm (J = 6.5 Hz); 1H, dd, 7.11 ppm (J = 8.0, 4.0 Hz); 1H, dd, 8.16 ppm (J = 8.0, 1-2 Hz); 1H, dd, 8.64 ppm (J = 4.0, 1-2 Hz ) . HRMS : Calculated - 201 . 0902 ; Found - 201 . 0864 .
Example 17 9-Amino-4 , 6-oxaza-l ,2,3, 4-tetrahydroacridine
Following the method of Example 16, but substituting 3-amino-4-cyano-pyridine for 2-amino-3-cyanopyridine, afforded the title compound (16%, m.p. 237-238°C). 1H-NMR (CDCl3+CD3OD, 300 MHz, δ): 2H, q, 2.06 ppm (J = 6.5 Hz); 2H, t, 2.59 ppm (J = 6.5 ppm); 2H, s, 3.56 ppm; 2H, t, 4.3 ppm (J = 6.5 Hz); 1H, d, 7.56 ppm (J = 6.0 Hz); 1H, d, 8.18 ppm (J = 6.0 Hz); 1H, s, 8.84 ppm. HRMS: Calculated - 201.0902; Found - 201.0892.
Example 18 9-Amino-5-aza-1,2,3,4-tetrahydro-1,4-methanoacridine
Following the method of Example 16, but substituting norcamphor for delta-valerolactone afforded the title compound (29%, m.p. 243-244°C). 1H-NMR (CDCl3+CD3OD, 300 MHz, δ ): 2H, m, 1.2-1.4 ppm; 1H, bd, 1.6 ppm (J = 6.0 Hz); 1H, bd, 1.81 ppm (J = 6.0 Hz); 2H, m, 1.88-2.04 ppm; 2H, bs, 3.26 ppm; 1H, bs, 3.43 ppm; 1H, bs, 3.48 ppm; 1H, dd, 7.23 ppm (J = 8.03, 3.0 Hz); 1H, d, 8.17 ppm (J = 8.0 Hz); 1H, d, 8.76 ppm (J = 3.0 Hz). HRMS: Calculated - 211.1109. Found - 211.1120.
Example 19 9-Amino-6-aza-1,2,3,4-tetrahydro-1,4-methanoacridine Following the method of Example 16, but substituting norcamphor for delta-valerolactone and
3-amino-4-cyano-pyridine for 2-amino-3-cyano-pyridine, afforded the title compound (16%, m.p. 236-237°C). 1H-NMR (CDCl3+CD3OD, 300 MHz , δ) : 2H, bq, 1.3 ppm; 1H, bd, 1.62 ppm; 1H, bd, 1.83 ppm; 2H, m, 1.9-2.1 ppm; 2H, s, 3.4 ppm; 1H, bs, 3.42 ppm; 1H, bs, 3.5 ppm; 1H, d,
7.6 ppm (J = 6.0 Hz); 1H, d, 8.31 ppm (J = 6.0 Hz); 1H, s, 9.07 ppm. HRMS: Calculated - 211.1109; Found - 211.1103.
Example 20 9-Cyclohexylmethylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine
A mixture of sodium hydride (60% oil, 110 mg, 2.75 mmole), the title compound of Example 6 (600 mg, 2.75 mmole, cyclohexylmethyl bromide (487 mg, 2.75 mmole) and dimethylformamide (3.0 ml) were heated with stirring at 25°C for 12 hours and then at 65°C for 12 hours. At the end of this period, the reaction mixture was quenched by pouring it into water (45 ml) and the resulting mixture was then extracted with ethyl acetate (3 x 35 ml) . The combined organic layer was washed with water (2 x 40 ml) and dried (anhydrous MgSO4). The ethyl acetate was removed under vacuum to afford a residue which was loaded on a flash chromatography column packed with silica gel. Elution with ethyl acetate afforded an oil which solidified on standing. Trituration of this solid with pentane afforded the title compound (110 mg, 13%) as a tan crystalline solid (m.p. 100°C). 1H-NMR (CDCl3, 300 MHz δ): 2H, m, 0.9-1.04 ppm; 3H, m, 1.04-1.32 ppm; 6H, m, 1.6-1.86 ppm; 2H, m, 1.88-2.04 ppm; 2H, t, 2.79 ppm (J = 6.0 Hz); 2H, bs, 3.17 ppm; 2H, t, 4.38 ppm (J = 6.0 Hz); 1H, bd, 5.79 ppm (J = 20 Hz); 1H, dd, 6.84 ppm (J = 140, 7.5 Hz); 1H, dd , 7.32 ppm; 1H, d, 7.48 ppm (J = 8.2 Hz). HRMS: Calculated - 314.1759; Found - 314.1787. TLC : (ethylacetate) Rf = 0.35.
Example 21 9-Cyclohexylethylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine
Following the method of Example 20, but substituting cyclohexylethyl bromide for cyclohexylmethyl bromide, afforded the title compound (34%). 1H-NMR (CDCl3, 300 MHz, δ): 2H, m, 0.8-1.02 ppm; 4H, m, 1.02-1.4 ppm; 2H, m, 1.44-1.56 ppm; 5H, bd, 1.56-1.8 ppm; 2H, q, 1.92-2.04 ppm (J = 6.0 Hz); 2H, t, 2.8 ppm (J = 6 Hz); 2H, bt, 3.33 ppm; 2H, t, 4.36 ppm (J = β
Hz); 1H, bd, 5.6 ppm (J = 20 Hz); 1H , dd, 6.38 ppm (J = 14.0, 7.5 Hz); 1H, dd, 7.24-7.38 ppm; 1H, d, 7.48 ppm (J = 8.2 Hz). HRMS: Calculated - 328.1951; Found - 328.1909. Analysis: Calculated for C20H25N2OF: 73.14%C; 7.67%H; 8.53%N. Found: 73.23%C; 7.93%H; 8.52%N. TLC: (ethyl acetate) Rf = 0.45. Example 22
9-Benzvlamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine
Following the method of Example 20, but substituting benzyl bromide for cyclohexylmethyl bromide, afforded the title compound (38%, m.p.
134-135°C). 1H-NMR (CDCl3, 300 MHz , δ ) : 2H, q, 1.98 ppm (J = 6 H 2H, t, 2.87 ppm (J = 6.0 Hz); 2H, t, 4.37 ppm (J Hz); 2H, bs , 4.48 ppm; 1H, bd, 5.87 ppm (J = 20 Hz); , dd, 6.84 ppm (J = 14, 7.5 Hz); 6H, m, 7.22-7.4 ppm; 1H, d, 7.52 ppm (J = 8.2 Hz). HRMS: Calculated - 308.1325; Found - 308.1316. Analysis: Calculated for C19H17N2OF:74.01%C; 5.56%H; 9.08%N. Found: 73.68%C; 5.61%H; 9.01%N. TLC: (ethyl acetate) Rf = 0.37. Example 23
9-Phenethylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine
Following the method of Example 20 but substituting (2-bromoethyl) benzene for cyclohexylmethyl bromide afforded the title compound (20%, m.p.
125-126°C). 1H-NMR (CDCl3, 300 MHz , δ ) : 2H, q, 1.92 ppm (J = 6 Hz); 2H, t, 2.69 ppm (J = 6.0 Hz); 2H, m, 2.9-3.0 ppm; 2H, bt, 3.38 ppm; 2H, m, 4.3-4.42 ppm; 1H, bd, 5.96 ppm (J = 20 Hz); 1H, dd, 6.78 ppm (J = 14, 7.5 Hz); 1H, d, 7.14 ppm (J = 8.6 Hz); 6H, m, 7.22-7.4 ppm. HRMS: Calculated - 322.3809; Found- 322.1486. TLC: (ethyl acetate) Rf = 0.53.
Example 24 9-Phenpropylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine
Following the method of Example 20, but substituting l-bromo-3-phenylpropane for cyclohexylmethyl bromide, afforded the title compound (53% oil), 1H-NMR (CDCl3, 300 MHz, δ): 4H, m, 1.82-2.02 ppm; 4H, m, 2.62-2.78 ppm; 2H, bs, 2.34 ppm; 2H, t, 4.35 ppm (J = 6.0 Hz); 1H, bd, 5.7 ppm (J = 20 Hz); 1H, dd , 6.86 ppm (J = 14, 7.5 Hz); 6H, m, 7.04-7.4 ppm; 1H, d, 7.51 ppm (J = 8.2 Hz). HRMS: Calculated - 336.1638; Found - 336.1649. TLC: (ethyl acetate) Rf = 0.38. Example 25
9-(3,3-Diphenylpropylamino)-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine
Following the method of Example 20, but substituting 1-bromo-3,3-diphenylpropane for cyclohexylmethyl bromide, afforded the title compound (32%, m.p.
134-135°C). 1H-NMR (CDCl3 , 300 MHz, if): 2H, q, 1.9 ppm (J = 6 Hz); 2H, q, 2.36 ppm (J = 6.0 Hz); 2H, t, 2.51 ppm (J = 6 Hz); 2H, bs, 3.32 ppm; 1H, t, 4.0 (J = 6 Hz); 2H, t, 4.31 ppm (J = 6 Hz); 1H, bs , 5.72 ppm (J = 20 Hz); 1H, dd , 6.9 ppm (J = 14.0, 7.5 Hz); 10H, m, 7.1-7.3 ppm; 1H, dd, 7.3-7.4 ppm; 1H, d, 7.52 ppm (J = 8.2 Hz). HRMS: Calculated - 412.1951; Found - 412.2004.
Analysis: Calculated for C27H25N2OF: 78.62%c; 6.11%H; 6.79%N. Found: 78.08%C; 5.95%H; 6.70%N. TLC: (ethyl acetate) Rf = 0.48.
Example 26 9-Amino-4-thia-1,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting delta-thiovalerolactone for delta-valerolactone afforded the title compound (4%,m.p.190°C). 1H-NMR
(CDCl3, 300 MHz, δ): 2H, m, 2.22-2.3 ppm; 2H, t, 2.73 ppm (J = 6.5 Hz); 2H, m, 3.1-3.2 ppm; 2H, bs, 4.66 ppm; 1H, t, 7.32 ppm (J=8 Hz); 1H, t, 7.54 ppm (J = 8 Hz); 1 H, d, 7.62 ppm (J=8 Hz); 1H, d, 7.8 ppm (J = 8 Hz).
HRMS: Calculated - 216.0723; Found - 216.0735.
TLC: (90:10:1-methylene chloride : methanol : 28% aqueous ammonia) Rf-0.61.
Example 27 9-Amino-3-methyl-4-oxa-1,2,3,4-tetrahydroacridine
Following the method of Example 7, but substituting 6-methyl-tetrahydropyran-2-one for delta-valerolactone, afforded the title compound (23%,m.p.202-203°C). 1H-NMR (CDCl3 , 300 MHz,δ): 3H, d, 1.45 ppm (J = 6.5 Hz); 1H, m, 1.7-1.84 ppm; 1H, m, 2.04-2.18 ppm; 2H, m, 2.58-2.64 ppm; 1H, m, 4.22-4.36 ppm; 2H, bs, 4.69ppm; 1H, t, 7.22 ppm (J = 7.5 Hz); 1H, t, 7.47 ppm (J = 7.5 Hz); 1H, d, 7.58 ppm (J = 7.5 Hz); 1H, d, 7.71 ppm (J = 7.5 Hz). HRMS: Calculated - 214.269; Found - 214.1138. Example 28
9-Amino-3-methyl-8-fluoro-4-oxa-1,2,3,4-tetrahydroacri- dine
Following the method of Example 7, but substituting 6-methyl-tetrahydropyran-2-one for delta-valerolactone and 2-amino-6-fluorobenzonitrile for anthranilonitrile afforded the title compound (13%, m.p. 217-218°C) . 1H-NMR (CDCl3 , 300 MHz,δ) : 3H, d, 1.45 ppm (J = 6.5 Hz) ; 1H, m, 2.65-2.84 ppm; 1H, m, 2.06-2.19 ppm; 2H, m, 2.5-2.6 ppm: 1H, m, 4.21-4.38 ppm; 2H, bs , 5.25 ppm; 1H, dd, 6.8 ppm (J = 7.5, 14
Hz); 1H, dd, 7.32 ppm (J = 8 Hz, 14.0 Hz); 1H, d, 7.5 ppm. (J = 8 Hz). HRMS: Calculated - 232.1026; Found - 232.1012 TLC: (90 : 10 : 1-methylene chloride : methanol : 28% aαrueous ammcnia) Rf-0.76. Example 29
9-Amino-8-fluoro-2-thia-1,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting tetrahydrothiopyran-4-one for delta-valerolactone and 2-amino-6-fluorobenzonitrile for anthranilonitrile, afforded the title compound
(19%, m.p. 175-176°C). 1H-NMR (CDCl3, 300 MHz,δ): 2H, t, 2.96 ppm (J = 6.2 Hz); 2H, t, 3.3 ppm (J = 6.2 Hz);
2H, s, 3.6 ppm; 2H, bs, 5.34 ppm; 1H, dd, 6.94 ppm (J =
6.2, 14 Hz); 1H, dd, 7.42 ppm (J = 8.6, 14 Hz); 1H, d, 7.61 ppm (J = 8.6 Hz). HRMS: Calculated - 234.067;
Found - 234.0605; TLC: (ethyl acetate) Rf - 0.23. Example 30 9-Amino-1,2,3,4-tetrahydro-1,4-ethanoacridine Following the method of Example 1, but substituting bicyclo [2.2.2]octan-2-one for norcamphor afforded the title compound (20%, m.p. 197-199°C). 1H-NMR (CDCl3 , 300 MHz , δ ) : 2H , m , 1. 4-1 . 58 ppm; 2H , m , 1.58-1.74 ppm; 4H, m, 1.8-2.0 ppm; 2H, bs, 3.2 ppm; 2H, bs, 4.65 ppm; 1H, t, 7.4 ppm (J = 8.5Hz); 1H, t, 7.58 ppm (J = 8.5 Hz); 1H, d, 7.71 ppm (J = 8.5 Hz); 1H, 7.97 ppm (J = 8.5 Hz). TLC: (90 : 10 : 1-methylene chloride :methanol: 28% aqueous ammonia) Rf-0.35.
Example 31 2,3-Dihydrofuro[2,3-b1quinolin-4-amine Following the method of Example 7 , but substituting gamma-butyrolactone for delta-valerolactone afforded the title compound (m.p. 300°C dec). 1H-NMR (CDCl3, 300 MHz,δ): 2H, t, 3.17 ppm (J = 8 Hz); 2H, bs, 4.6 ppm; 2H, t, 4.69 ppm (J = 8 Hz); 1H, t, 7.28 ppm (J = 8 Hz); 1H, t, 7.53 ppm (J = 8 Hz); 1H, d, 7.62 ppm (J = 8 Hz); 1H, d, 7.77 ppm (J = 8 Hz). LRMS: Found - 186.
Example 32 6H-[1]Benzopyrano[4,3-b]quinolin-7-amine Following the method of Example 7, but substituting 4-chromanone for delta-valerolactone afforded the title compound (3%, m.p. 275°C dec). 1H-NMR (DMSO, 300 MHz,δ): 2H, s, 5.3 ppm; 1H, d, 6.97 ppm (J = 8.2 Hz); 1H, t, 7.08 ppm (J = 7.0 Hz); 2H, m, 7.15-7.4 ppm; 1H , t, 7.57 ppm (J = 7.0 Hz); 1H, d, 7.78 ppm (J = 7.0 Hz); 1H, d, 8.16 ppm (J = 8.0Hz); 1H, dd, 8.24 ppm (J = 7.0, 2.0 Hz). HRMS: Calculated - 248.287; Found - 248.0908; TLC : (90 : 10 : 1-methylene chloride :methanol: 28% aqueous ammonia) Rf-0.65. Examp-le 33
6H- [1] Benzothiopyrano [4 ,3-bJquinolin-7-amine Following the method of Example 7, but substituting thiochroman-4-one for delta-valerolactone afforded the title compound (13%, m.p. 211-212°C). 1 H-NMR (CDCl3, 300 MHz, δ): 2H, s, 3.94 ppm; 2H, bs 4.7 ppm; 4H, m, 7.23-7.44 ppm; 1H, t, 7.61 ppm (J = 7 Hz); 1H, d, 7.7 ppm (J = 7 Hz); 1H, d, 8.02 ppm (J = 7.0 Hz); 1H, 8.5 ppm (J = 7.0,2.0 Hz). HRMS: Calculated - 264.0721; Found - 264.0715; TLC: (90:10:1-methylene chloride:methanol: 28% aqueous ammonia) Rf-0.77.
Example 34 9-Methylamino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine Following the method Example 20, but substituting iodomethane for cyclohexylmethyl bromide afforded the title compound (for HCl salt:m.p. 240°C). 1H-NMR (DMSO , 300 MHz , δ) : 2H, m, 2.0 ppm; 2H, t , 2.95 ppm (J = 6.5Hz); 3H, bd, 3.3 ppm; 2H, t, 4.53 ppm (J = 6.5 Hz); 1H, dd, 7.34 ppm (J = 8, 14 Hz); 1H, dd, 7.44 ppm (J = 8.0Hz); 1H, m, 7.7-7.8 ppm; 1H, bm, 7.94-8.06 ppm.
Example 35 2,3-Dihydro-8-fluorothieno[3,2-b]quinolin-9-amine (Compound A) and
1,3-Dlhydro-8-fluoro-thieno[3,4-b]quinolin-9-amine (Compound B)
Following the method of Example 12 but substituting 2-amino-6-fluorobenzonitrile for anthranilonitrile afforded a 1:1 mixture of the two title compounds. Compound A (m.p. 137°C) : 1H-NMR (CDCl3 , 300 MHz , δ ) : 4H, m, 3 . 48 ppm; 2H , bs , 5 . 09 ppm ; 1H, dd, 6.98 ppm (J = 7.3, 14.5 Hz); 1H, dd, 7.38 ppm (J = 7.3, 10.5 Hz); 1H, d, 7.64 ppm (J = 10.5Hz); TLC:
(ethyl acetate) Rf-0.38.
Compound B (m.p. 198°C dec.) 1H-NMR (CDCl3, 300 MHz, δ): 2H, s, 4.09 ppm; 2H, s, 4.38 ppm; 2H, bs, 5.3 ppm; 1H, dd, 7.0 ppm (J = 7.3, 14.5 Hz); 1H, dd, 7.47 ppm (J = 7.3, 10.5 Hz); 1H, d, 7.68 ppm (J = 10.5Hz); TLC: (ethyl acetate) Rf-0.49.
Example 36 9-Amino-1,2-dihyroacridine-4(32)-one Following the method of Example 1, but substituting 1,2-cyclohexanedione for norcamphor, afforded the title compound (11%, m.p. 240°C dec). 1H-NMR (CDCl3 , 300 MHz , δ) : 2H , quin , 2. 31 ppm; 4H , mt , 2.8-2.95 ppm; 2H, bs, 4.95 ppm; 1H, t, 7.29 ppm (J =
8.5 Hz); 1H, t, 7.64 ppm (J = 8.5 Hz); 1H, d, 7.74 ppm (J = 8.5 Hz); 1H, d, 8.2 ppm (J = 8.51Hz); HRMS: Calculated - 212.0950; Found - 212.0941; TLC: (90: 10: 1-methylene chloride: methanol:28% aqueous ammonia) Rf-0.41.
Example 37 8-fluoro-9-amino-1,2,3,4-tetrahydroacridine
To a stirred solution of cyclohexanone (1.0 g, 10.0 mmole) in methylene chloride (10 ml) at -20°C, a IM solution of titanium (IV) chloride in methylene chloride (20 ml) was added. The reaction mixture became yellow in color and to it a mixture of triethylamine (2.0 g,20 mmole) and 2-amino-6-fluorobenzonitrile (1.36 g,10.0 mmole) in methylene chloride (30 ml) were added. The reaction mixture immediately became dark in color and was allowed to warm to room temperature (about 25°C) and stirred further for 15 hours. At the end of this period, the reaction mixture was treated with 12% aqueous NaOH (100 ml), and methylene chloride (100 ml). The reaction mixture was then filtered through a 2 inch diatomaceous earth pad (Celite (trademark)) which was washed with methylene chloride (50 ml) and water (100 ml) . The organic layer was separated, washed with water (1x30 ml) and dried (anhydrous MgSO4). The methylene chloride was removed under vacuum to afford an oil which was triturated with ether to give the title compound as a white solid (218 mg, 10%, m.p. 175°C). 1H-NMR (CDCl3, 300MHz , δ) : 4H, m, 2. 0 ppm; 2H , t , 2. 59 ppm (J = 7. 0 Hz); 2H, t, 3.06 ppm (J = 7.0 Hz); 2H, bs, 5.37 ppm; 1H, dd, 7.0 ppm (J = 7.5, 14 Hz); 1H, dd, 7.46 ppm (J = 8, 16 Hz); 1H d, 7.72 ppm (J = 8.5 Hz). HRMS: Calculated - 216.1053; Found - 216.1039.
Example 38 9-Amino-8-methyl-1,2,3,4-tetrahydroacridine
Following the method of Example 37, but substituting 2-amino-6-methylbenzonitrile for 2-amino-6-fluorobenzonitrile, afforded the title compound (11%, m.p. 143-145°C). 1H-NMR (CDCl3, 300 MHZ, δ) : 1H, d, 7.68 ppm (J = 8 Hz); 1H, t, 7.34 ppm (J = 8 Hz); 1H, d, 7.02 ppm (J = 8 Hz); 2H, bs, 4.89 ppm; 2H, t, 2.95 (J = 6 Hz); 3H, s, 2.92 ppm; 2H, t, 2.49 ppm (J = 6 Hz); 4H, m, 1.8-2.0 ppm; HRMS: Calculated - 212.1313; Found - 212.1273; TLC: (90 : 10 :1-methylene chloride:methanol:28% aqueous ammonia) Rf-0.23.
Example 39 9-Amino-8-chloro-1,2,3,4-tetrahydroacridine Following the method of Example 37, but substituting 2-amino-6-chlorobenzonitrile for 2-amino-6-fluorobenzonitrile, afforded the title compound (23%, m.p. 144-145°C). 1H-NMR (CDCl3, 300 MHz, δ) : 1H, d, 7.75 ppm (J = 8 Hz); 1 H, t, 7.35 ppm (J=8 Hz); 1H, d, 7.27 ppm (J = 8 Hz); 2H, bs , 5.81 ppm; 2H, t, 2.96 ppm (J = 6 Hz); 2H, t, 2.49 ppm (J = 6 Hz); 4H, m, 1.96 - 1.86 ppm; HRMS: Calculated - 232.0770; Found - 232.0777; TLC: (90 : 10 : 1-methylene chloride: methanol: 28% aqueous ammonia) Rf-0.62.
Example 40 4-Amino-5-fluoro-2,3-pentamethylenequinoline Following the method of Example 37, but substituting cvcloheptanone for cyclohexanone, afforded the title compound (22%, m.p. 203°C). H-NMR (CDCl3, 300 MHz, δ): 1H, d, 7.67 ppm (J = 8 Hz); 1H, dd, 7.39 ppm (J = 8 Hz); 1H, dd, 6.96 ppm (J = 7, 14 Hz); 2H, bs, 5.34 ppm; 2H , m, 3.09 ppm; 2H, m, 2.7 ppm; 6H, m, 1.6-2.0 ppm; HRMS: Calculated - 230.1219; Found - 230.1235; TLC: (ethyl acetate) Rf-0.31.
Example 41 4-Amino-5-chloro-2,3-pentamethylenequinoline Following the method of Example 37, but substituting cycloheptanone for cyclohexanone and 2-amino-6-chlorobenzonitrile for 2-Amino-6-fluorobenzonitrile, afforded the title compound (11%, m.p. 194-195 °C) . 1H-NMR (CDCl3 , 300 MHz , δ ) : 1H , d , 7 . 79 ppm (J = 7 Hz); 2H, m, 7.30-7.39 ppm; 2H, bs, 5.85 ppm; 2H, m, 3.08 ppm; 2H, m, 2.69 ppm; 6H, m, 1.65-2.0 ppm; HRMS: Calculated - 246.0924; Found - 246.0914; TLC: (ethyl acetate) Rf-0.34.
Example 42 4-Amino-5-fluoro-2,3-trimethylenequinoline Following the method of Example 37, but substituting cyclopentanone for cyclohexanone, afforded the title compound (6%, m.p. 179-181°C). 1H-NMR (CDCl3, 300 MHz,δ): 1H, d, 7.65 ppm (J = 8 Hz); 1H, dd, 7.4 Hz (J = 8 Hz); 1H, dd, 6.93 ppm (J = 7.14 Hz); 1H, bs, 5.10 ppm; 2H, t, 3.07 ppm (J = 8 Hz); 2H, t, 2.8 ppm (J = 8 Hz); 2H, quin, 2.1-2.23 ppm (J = 8 Hz); HRMS: Calculated - 202.0906; Found - 202.0909; TLC: (90:10:1-methylene chloride:methanol:28% aqueous ammonia) Rf-0.52.
Example 43 9-Amino-8-chloro-4-oxo-1,2,3,4-tetrahydro,cridine Following the method of Example 7, but substituting 2-amino-6-chlorobenzonitrile for anthranilonitrile, afforded 'the title compound (15%, m.p. 205°C). 1H-NMR (CDCl3, 300 MHz,δ): 1H, d, 7.62 ppm (J = 7 Hz); 1H, t, 7.31 ppm (J = 7 Hz); 1H, d, 7.19 ppm (J = 7 Hz); 2H, bs, 5.81 ppm; 2H, t, 4.31 ppm (J = 6 Hz); 2H, t, 2.52 ppm (J = 6 Hz); 2H, m, 2.11 ppm; HRMS: Calculated - 234.0560; Found - 234.0565; TLC: (ethyl acetate) Rf-0.27.
Example 44 9-Amino-8-methyl-4-oxa-1,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting 2-amino-6-methylbenzonitrile for anthranilonitrile, afforded the title compound (20%, m.p. 177-179°C). 1H-NMR (CDCl3, 300 MHz , δ) : 1H, d, 7.56 ppm (J = 7 Hz); 1H, t, 7.31 ppm (J = 7 Hz); 1H, d, 6.95 ppm (J = 7 Hz); 2H, bs, 4.93 ppm; 2H, t, 4.29 ppm (J = 6 Hz); 3H, s, 2.89 ppm; 2H, t, 2.52 ppm (J = 6 Hz); 2H, m, 2.08-2.11 ppm; HRMS: Calculated - 214.1106; Found - 214.1097; TLC: (ethyl acetate)
Rf-0.27.
Example 45 9-Amino-8-methoxy-l ,2,3, 4-tetrahydroacridine
Following the method of Example 37, but substituting 2-amino-6-methoxybenzonitrile for 2-amino-6-fluorobenzonitrile, afforded the title compound (14%, m.p. 187-188°C). 1H-NMR (CDCl3, 300 MHz,δ): 1H, d, 7.45 ppm (J = 8.0 Hz); 1H, t, 7.37 ppm (J = 8 Hz); 1H, d, 6.64 ppm (J = 8 Hz); 2H, bs, 5.88 ppm; 3H, s, 3.96 ppm; 2H, t, 2.95 ppm (J = 7 Hz) ; 2H, t, 2.46 ppm (J = 7 Hz); 4H, m, 1.94-1.85 ppm; HRMS : Calculated - 228.1233; Found - 228.1277; TLC: (90 :10:1-methylene chloride:mεthanol: 28% aqueous ammonia) Rf-0.20.
Example 46
9-Amino-8-methoxy-4-oxa-1,2,3,4-tetrahydroacridine Following the method of Example 7, but substituting 2-amino-6-methyoxybenzonitrile for anthranilonitrile afforded the title compound (11%, m.p. 205-207°C). 1H-NMR (CDCl3 , 300 MHz, δ): 2H , m, 7.33 ppm; 1H, dd, 6.57 ppm (J = 3 , 6 Hz); 2H, bs, 5.92 ppm; 2H, t, 4.29 ppm (J = 2, 6 Hz); 3H, s, 3.95 ppm; 2H, t, 2.5 ppm (J = 2 , 6 Hz); 2H, m, 2.13-2.07 ppm;
TLC: (90:10:1-methylene chloride:methanol:28% aqueous ammonia) Rf-0.49.
Example 47 The ability of the title compounds of Examples 1-16, 18, 26-29, and 35-46 to inhibit brain acetylcholinesterase was determined by the spectrophotometric method of G. L. Ellman et al. (Biochemical Pharmacology, 7 , 88 (1961)). All of the compounds had IC50 (molar) values between 5 μM and 0.1 μM.

Claims

A compound of the formula
Figure imgf000038_0001
wherein A is selected from the group consisting of
and
Figure imgf000038_0002
Figure imgf000038_0003
Figure imgf000038_0004
Figure imgf000038_0005
Figure imgf000038_0006
wherein one of the CH moieties at positions a, b, c and d of formula 1 may be replaced by a nitrogen atom or each of the CH moieties at positions a and d, a and c or b and d may be replaced by a nitrogen atom; B is selected from the group consisting of
Figure imgf000039_0002
and
Figure imgf000039_0003
Figure imgf000039_0001
wherein each broken line represents an optional double bond; R1 is hydrogen or C1-C6 alkyl;
R 3 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, di(C1-C6 alkylamino)-C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl, halogen, hydroxy, nitro, phenyl, substituted phenyl, phenyl-C1-C6 alkyl, substituted phenyl-C1-C6 alkyl, diphenyl-C1-C6 alkyl wherein one or both of the phenyl groups may be replaced with a substituted phenyl group, furyl-C1-C6 alkyl, thienyl-C1-C6 alkyl, phenyloxy, substituted phenyloxy, NHCOR5 and NR6R7, wherein the phenyl moieties on the substituted phenyl and substituted phenylalkyl groups are substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, trifluoromethyl, C1-C6 alkoxy-C1-C6 alkyl, hydroxy and nitro, and wherein R5, R6 and R7 are independently selected from C1-C6 alkyl and C1-C6 alkanoyl; R2 is independently selected from the group consisting of 1,4-dihydropyridyl-C1-C6 alkanoyl, C1-C6 alkyl-1,4-dihydropyridyl-C1-C6-alkanoyl, and the possible definitions set forth above for R3, except that R2 cannot be hydroxy, halogen, C1-C6 alkoxy, phenyloxy or substituted phenyloxy; R 4 is independently selected from the possible definitions set forth above for R3, except that R 4 cannot be halogen, nitro, NHCOR5 or
NR6R7; n is 1, 2 or 3 ; Z1 is NH, O, S or NR8 wherein R8 is C1-C6 alkyl or C1-C6 alkanoyl; Z 2 is O or S; Z3 and
Z are independently selected from (CH2)p, O, S, S=O and SO2, with the proviso that at least one of Z3 and
Z 4 is (CH2)p; Z5 is CH2, O, S, S=O or SO2; Z6 is O, S,
S=O or SO2; p is 1, 2 or 3; q is 1 or 2; Y1 is CH2,
CHOH, O, C=O, S, S=O or SO2; Y2 is CH2 , CH, O, S, S=O or SO2; and Y3 is CHOH, CH2, CH or C=O, with the proviso that the group of the formula 8 may have a double bond only when both Y 2 and Y3 are CH, with the proviso that when A is a group of the formula 1 wherein R3 is hydrogen and there is no nitrogen at position a, b, c or d or A is a group of the formula 3 or 4, only one of Y 1 and Y2 can be CH2, and with the proviso that when A is a group of the formula 1 wherein R 3 is hydrogen and there is no nitrogen at position a, b, c or d, only one of Z 3 and Z4 can be (CH2)p; and pharmaceutically acceptable salts thereof.
2. A compound according to claim 1, with the proviso that when A is a group of the formula 1 wherein there is no nitrogen at position a, b, c or d or A is a group of the formula 3 or 4, only one of Y 1 and Y2 can be CH 2.
3 . A compound according to claim 2 , wherein R1 ,
R2 and R4 are hydrogen and R3 is hydrogen or halogen .
3
4. A compound according to claim 3, wherein R is hydrogen or fluorine.
5. A compound according to claim 2, said compound being selected from the group consisting of compounds of the formula I wherein A is a group of the formula 1, wherein one of the CH moieties at positions a and b of formula 1 may be replaced by a nitrogen atom or A is a group of the formula 3; B, R1, R2, R3, R4, Z3 , Z4 , Z5 , Y3 and q are as defined in claim 1; n is 1 or 2; Z6 is S; and p is 1 or 2; with the proviso that
(a) when A is a group of the formula 1 wherein there is no nitrogen at either position a or position b, Z3 is O, S or CH2; R4 is hydrogen or C1-C6 alkyl; Z4 is (CH2)p, wherein p is 1 or 2, or S; Y1 is CH2, C=O, O, or S, and Y2 is CH2, O or S, with the proviso that only one of Y1 and Y2 can be CH2;
(b) when A is a group of the formula 1 wherein there is a nitrogen at either position a or position b, Y1 is O, S or CH2 and Y2 is CH2; and
(c) when A is a group of the formula 3 , Y1 is O or S; and Y2 is CH2; and pharmaceutically acceptable salts thereof.
6. A compound according to claim 5, wherein R1, R2 and R4 are hydrogen and R3 is hydrogen or halogen.
7. A compound according to claim 6, wherein R3 is hydrogen or fluorine.
8. A compound according to claim 2, wherein B is a group of the formula 7 or 8 .
9. A compound according to claim 8, wherein R1,
R 2 and R4 are hydrogen and R3 is hydrogen or halogen.
10. A compound according to claim 9, wherein R3 is hydrogen or fluorine.
11. A compound according to claim 5, wherein B is a group of the formula 7 or 8.
12. A compound according to claim 11, wherein R1, R2 and R4 are hydrogen and R3 is hydrogen or halogen.
13. A compound according to claim 2, wherein R1,
R 2 and R4 are hydrogen and R3 is hydrogen or halogen.
14. A compound according to claim 1, wherein A is a group of the formula 1, wherein R3 is as defined for formula I, with the proviso that R3 may only be at position c of formula 1, and R 1,R2 and B are as defined in claim 1.
15. A compound according to claim 14, wherein R3 is halogen.
16. A compound according to claim 15, wherein R3 is fluorine.
17. A compound according to claim 1, wherein A is a group of the formula 1, wherein R3 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, nitro, NHCOR5, NR6R7 or trifluoromethyl, wherein R5,R6 and R7 are as defined in claim 1; and B is a group of the formula
Figure imgf000042_0001
wherein r is 2,3 or 4.
18. A compound according to claim 17, wherein R3 is at the c position of formula 1.
19. A compound according to claim 17, wherein R3 is halogen.
20. A compound according to claim 18, wherein R3 is halogen.
21. A compound according to claim 19, wherein R3 is fluorine.
22. A compound according to claim 20, wherein R3 is fluorine.
23. A compound according to claim 2, said compound being selected from the group consisting of:
9-amino-4-oxa-1,2,3,4-tetrahydroacridine; 9-amino-1,2,3,4-tetrahydro-1,4-methanoacridine; 9-amino-8-fluoro-1,2,3,4-tetrahydro-1,4-methanoacridine;
9-amino-2-oxa-1,2,3,4,-tetrahydroacridine; 9-amino-2-thia-1,2,3,4-tetrahydroacridine;
9-amino-8-fluoro-4-oxa-1,2,3,4-tetrahydroacridine;
9-amino-4-oxa-1,2,3,4,5,6,7,8-octahydroacridine;
2,3-dihydrothieno[3,2-b]quinoline-9-amine;
9-amino-5-aza-1,2,3,4-tetrahydroacridine;
2, 3-dihydro-8-fluoro-thieno[3,2-b]quinolin-9-amine;
9-amino-1,2-dihydroacridine-4(3H)-one; 1,3-dihydro-8-fluoro-thieno[3,4-b]-quinolin-9-amine;
9-amino-4-thia-1,2,3,4-tetrahydroacridine;
9-amino-8-fluoro-2-thia-1,2,3,4-tetrahydroacridine; and the pharmaceutically acceptable salts of the foregoing compounds.
24. A compound according to claim 17, said compound being 8-fluoro-9-amino-1,2,3,4-tetrahydroacridine or a pharmaceutically acceptable salt thereof.
25. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a memory enhancing effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
26. A method of treating Alzheimer's disease comprising administering to a patient in need of such treatment a memory enhancing effective amount of a compound according to claim 1.
3
27. A compound according to claim 2, wherein Y is CH2, and at least one of Z 3 and Z4 is CH2; with the proviso that when A is a group of the formula 1 wherein
R 3 is hydrogen and there is no ni.trogen at posi.ti.on a, b, c or d, only one of Z 3 and Z4 can be (CH2)P .
PCT/US1988/001070 1987-10-05 1988-03-30 4-aminopyridine derivatives WO1989002740A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
IL87861A IL87861A0 (en) 1987-10-05 1988-09-28 4-aminopyridine derivatives
ES88309040T ES2072263T3 (en) 1987-10-05 1988-09-29 4-AMINOPYRIDINE DERIVATIVES.
DE3853863T DE3853863T2 (en) 1987-10-05 1988-09-29 4-aminopyridine derivatives.
AT88309040T ATE123024T1 (en) 1987-10-05 1988-09-29 4-AMINOPYRIDINE DERIVATIVES.
EP88309040A EP0311303B1 (en) 1987-10-05 1988-09-29 4-aminopyridine derivatives
MYPI88001105A MY104335A (en) 1987-10-05 1988-10-03 4-aminophridine deravatives
PL1988275056A PL159258B1 (en) 1987-10-05 1988-10-03 Method of obtaining derivatives of 4-aminopyridine
PT88656A PT88656B (en) 1987-10-05 1988-10-03 PROCESS FOR THE PREPARATION OF 4-AMINOPYRIDINE DERIVATIVES
AU23370/88A AU619213B2 (en) 1987-10-05 1988-10-04 4-aminopyridine derivatives
NO884400A NO176713C (en) 1987-10-05 1988-10-04 Analogous Process for Preparation of Therapeutically Active 4-Aminopyridine Derivatives
NZ226445A NZ226445A (en) 1987-10-05 1988-10-04 Aminopyridine derivatives and pharmaceutical compositions containing such
IE300388A IE60718B1 (en) 1987-10-05 1988-10-04 4-aminopyridine derivatives
DK553988A DK553988A (en) 1987-10-05 1988-10-04 4-AMINOPYRIDINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
CN88109023A CN1032440A (en) 1987-10-05 1988-10-04 The 4-aminopyridine derivatives class
KR1019880012933A KR900007243B1 (en) 1987-10-05 1988-10-04 4-amino pyridine derivatives
FI884553A FI93117C (en) 1987-10-05 1988-10-04 Analogous process for the preparation of therapeutically useful 9-aminotetrahydroacridine derivatives
YU184988A YU48197B (en) 1987-10-05 1988-10-04 4-AMINOPYRIDINE DERIVATIVES AND PROCEDURE FOR OBTAINING THEIR MIXTURES
HU885131A HU203082B (en) 1987-10-05 1988-10-04 Process for producing condensed 4-aminopyridine derivatives
JP63251742A JPH0692372B2 (en) 1987-10-05 1988-10-05 4-aminopyridine derivative
SU925010806A RU2039058C1 (en) 1988-03-30 1992-02-18 4-aminopyridine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US87/02546 1987-10-05
PCT/US1987/002546 WO1989002739A1 (en) 1987-10-05 1987-10-05 4-aminopyridine derivatives

Publications (1)

Publication Number Publication Date
WO1989002740A1 true WO1989002740A1 (en) 1989-04-06

Family

ID=22202587

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1987/002546 WO1989002739A1 (en) 1987-10-05 1987-10-05 4-aminopyridine derivatives
PCT/US1988/001070 WO1989002740A1 (en) 1987-10-05 1988-03-30 4-aminopyridine derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1987/002546 WO1989002739A1 (en) 1987-10-05 1987-10-05 4-aminopyridine derivatives

Country Status (12)

Country Link
KR (1) KR900007243B1 (en)
AT (1) ATE123024T1 (en)
DD (1) DD273633A5 (en)
EG (1) EG19973A (en)
FI (1) FI93117C (en)
MX (1) MX13270A (en)
MY (1) MY104335A (en)
PL (1) PL159258B1 (en)
PT (1) PT88656B (en)
RU (1) RU1816283C (en)
WO (2) WO1989002739A1 (en)
ZA (1) ZA887399B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897400A (en) * 1987-02-13 1990-01-30 Hoeschst-Roussel Pharmaceuticals, Inc. 9-amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds useful for incresing the cholinergic function in a mammal
US4927820A (en) * 1988-11-25 1990-05-22 Hoechst Roussel Pharmaceuticals Inc. Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine
US4994452A (en) * 1989-11-28 1991-02-19 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5002955A (en) * 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
US5013741A (en) * 1987-09-08 1991-05-07 Hoechst-Roussel Pharmaceuticals Incorporated N-[substituted alkylidene]-1,2,3,4-tetrahydro-9-acridinamines useful for enhancing the cholinergic function in a mammal
US5037833A (en) * 1988-07-25 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. N-[substituted alkylidene]fused-bicycloalkylidene quinolinamines useful for enhancing the cholinergic function in a mammal
US5112829A (en) * 1989-11-28 1992-05-12 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5210087A (en) * 1991-02-13 1993-05-11 Hoechst-Roussel Pharmaceuticals Inc. 9-aminotetrahydroacridines and related compounds
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5397785A (en) * 1989-11-08 1995-03-14 Mitsubishi Kasei Corporation 4-acylaminopyridine derivative
US5422350A (en) * 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US5466696A (en) * 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
CZ298367B6 (en) * 1997-02-26 2007-09-12 Hoechst Aktiengesellschaft Combined preparation used for treating dementia

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
US5929093A (en) * 1996-06-13 1999-07-27 Mayo Foundation For Medical Education And Research Bifunctional acetylcholinesterase reactivators
DE10111728A1 (en) * 2001-03-09 2002-09-12 Merck Patent Gmbh UV filter
EP1789420A2 (en) 2004-09-07 2007-05-30 Wyeth, A Corporation of the State of Delaware 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS
CN114853672B (en) * 2022-05-12 2023-06-23 中国人民解放军北部战区总医院 Tacrine derivatives as CDKs inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180580A (en) * 1976-11-08 1979-12-25 American Home Products Corp. Furo(3,4-b)quinolines
US4680298A (en) * 1983-05-31 1987-07-14 Schering Corporation Tricyclic anti-allergy and use as anti-inflammatory agents
US4680297A (en) * 1983-07-14 1987-07-14 Schering Corporation Tricyclic positive inotropic agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232945A (en) * 1962-08-13 1966-02-01 S E Massengill Company 7,8,9,10-tetrahalo-6h-cyclohepta-(b)-quinolines
US3318896A (en) * 1963-12-05 1967-05-09 Squibb & Sons Inc Production of 12-substituted-6, 7, 8, 9, 10, 11-hexahydrocycloocta[b]quinolines
GB1186061A (en) * 1966-03-14 1970-04-02 American Home Prod Benzonaphthyridine Derivatives
US3541066A (en) * 1968-09-16 1970-11-17 American Home Prod 2,3-dihydro-1,4-ethanobenzo(b)(1,5)naphthyridine derivatives
US4550113A (en) * 1982-08-19 1985-10-29 Nauchno-Issledovatelsky Institut Po Biologicheskikm Ispytaniyam Khimicheskikh Soedineny 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles
US4695573A (en) * 1984-10-25 1987-09-22 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4578394A (en) * 1984-12-10 1986-03-25 Hoechst-Roussel Pharmaceuticals Incorporated Cholinergic function increasing 3-[N-(pyridyl) carbamoyl]-1,4-dihydropyridines
US4652567A (en) * 1985-03-13 1987-03-24 Hoechst-Roussel Pharmaceuticals Inc. Benzo(c)-1,5-naphthyridines useful for treating a patient having drug induced memory impairment in need of memory enhancement

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180580A (en) * 1976-11-08 1979-12-25 American Home Products Corp. Furo(3,4-b)quinolines
US4680298A (en) * 1983-05-31 1987-07-14 Schering Corporation Tricyclic anti-allergy and use as anti-inflammatory agents
US4680297A (en) * 1983-07-14 1987-07-14 Schering Corporation Tricyclic positive inotropic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 92, Number 1, issued 1980, (Columbus, Ohio, USA), ARNE OSBIRK et al., "Phosamides. X. Phosphorus Pentaoxide Amine Mixtures and HMPT as Reagents in the Synthesis of 4-Amino- and 4-Dimethylamino-2,3-Polymethylene-quinolines", Abstract No. 6385a; & ACTA CHEM. SCAND., SER. B (1979), B33(5), 313-18 (Eng). *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897400A (en) * 1987-02-13 1990-01-30 Hoeschst-Roussel Pharmaceuticals, Inc. 9-amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds useful for incresing the cholinergic function in a mammal
US5002955A (en) * 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
US5013741A (en) * 1987-09-08 1991-05-07 Hoechst-Roussel Pharmaceuticals Incorporated N-[substituted alkylidene]-1,2,3,4-tetrahydro-9-acridinamines useful for enhancing the cholinergic function in a mammal
US5037833A (en) * 1988-07-25 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. N-[substituted alkylidene]fused-bicycloalkylidene quinolinamines useful for enhancing the cholinergic function in a mammal
US4927820A (en) * 1988-11-25 1990-05-22 Hoechst Roussel Pharmaceuticals Inc. Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine
US5861411A (en) * 1989-11-08 1999-01-19 Mitsubishi Chemical Corporation 4-Acylaminopyridine derivative
US5536728A (en) * 1989-11-08 1996-07-16 Mitsubishi Chemical Corporation 4-acylaminopyridine derivative
US5397785A (en) * 1989-11-08 1995-03-14 Mitsubishi Kasei Corporation 4-acylaminopyridine derivative
US4994452A (en) * 1989-11-28 1991-02-19 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5112829A (en) * 1989-11-28 1992-05-12 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5502203A (en) * 1991-02-13 1996-03-26 Hoechst-Roussel Pharmaceuticals Inc. Certain 6,7-dihydro-3(2-nitrophenyl)-1,2-benzisoxazol-4(5H)-ones as intermediates
US5210087A (en) * 1991-02-13 1993-05-11 Hoechst-Roussel Pharmaceuticals Inc. 9-aminotetrahydroacridines and related compounds
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5466696A (en) * 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
US5422350A (en) * 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
CZ298367B6 (en) * 1997-02-26 2007-09-12 Hoechst Aktiengesellschaft Combined preparation used for treating dementia

Also Published As

Publication number Publication date
EG19973A (en) 1996-10-31
WO1989002739A1 (en) 1989-04-06
PL275056A1 (en) 1989-05-30
DD273633A5 (en) 1989-11-22
PL159258B1 (en) 1992-12-31
PT88656A (en) 1988-11-01
FI884553A (en) 1989-04-06
MX13270A (en) 1993-06-01
FI93117B (en) 1994-11-15
ZA887399B (en) 1990-05-30
FI93117C (en) 1995-02-27
KR900007243B1 (en) 1990-10-06
PT88656B (en) 1992-12-31
RU1816283C (en) 1993-05-15
MY104335A (en) 1994-03-31
KR890006590A (en) 1989-06-14
ATE123024T1 (en) 1995-06-15
FI884553A0 (en) 1988-10-04

Similar Documents

Publication Publication Date Title
WO1989002740A1 (en) 4-aminopyridine derivatives
EP0311303A2 (en) 4-aminopyridine derivatives
TW550265B (en) Substituted pyrido- or pyrimido-containing 6,6-or 6,7-bicyclic derivatives
KR930002489B1 (en) Benzo |5,6¨ cycloheptapyridines and process for preparation theirof
IE61281B1 (en) Hexa-cyclic compound
NZ198220A (en) Piperidylidene derivatives and pharmaceutical compositions
EP0555347A1 (en) SUBSTITUTED INDOLIZINO 1,2-b]QUINOLINONES
US5420134A (en) Substituted hexahydrobenzo[A]phenanthridines
US5968949A (en) Substituted hydroisoquinoline derivatives and their use as pharmaceuticals
US5202440A (en) Certain 9-amino-2-(or 4)-oxa 1,2,3,4-tetrahydro- or 1,2,3,4,5,6,7,8-octahydro-acridines
US5959110A (en) Fused isoquinolines as dopamine receptor ligands
US4612312A (en) Glutarimide antianxiety and antihypertensive agents
JPS60197687A (en) Indolophenantridines
AU617651B2 (en) Fused benzazepines
US4511569A (en) Tricyclic lactams and derivatives useful in increasing cardiac contractility
RU2039058C1 (en) 4-aminopyridine derivatives
JP2835050B2 (en) Heteroalkylenequinolineamine and method for producing the same
EP0441598B1 (en) Spiroisoindole compounds
AU622506B2 (en) Novel derivatives of 1,7-(imidazo-(1,2-a)pyridine)5&#39;-6&#39;h) ones
CA2128275A1 (en) 12-hetero substituted 6,11-ethano-6,11-dihydrobenzo¬b| quinolizinium salts and compositions and method of use thereof
US4474786A (en) Tricyclic lactams and derivatives useful in increasing cardiac contractility
JP2005501041A (en) 2- (Aminomethyl) -tetrahydro-9-oxa-1,3-diaza-cyclopenta [a] naphthalenyl derivatives having antipsychotic activity
WO1997041125A1 (en) Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
CS228543B2 (en) Method for the production of new trans-/6a,10a/diastereomeric 9-amino-1-acetoxyoktahydrobenzo/c/quinoline derivates
PL144516B1 (en) Method of obtaining novel aromatic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): FI HU NO RO SU US

WD Withdrawal of designations after international publication

Free format text: FI,HU,NO,RO,SU